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SUMMARY 
Part I 
The proviral insertion in murine (PIM) lymphoma proteins are a serine 
/threonine kinase family composed of three isoforms: PIM1, PIM2 and PIM3 which 
play a critical role in the control of the cell survival, proliferation, homing, 
migration, apoptosis inhibition, micro-environmental signaling and drug 
resistance.  Overexpression of PIM kinases has been reported in several human 
tumors, mainly in hematological cancers. PIM kinases are cytokine dependent 
and mainly regulated by the Janus Kinase/Signal Transducer Activator of 
Transcription (JAK/STAT) signaling pathway. This is mainly activated by members 
of the Interleukin-6 (IL-6) family, but also others. Also Leukemia Inhibitory Factor 
(LIF) and Oncostatin M (OSM) belong to this family. Different trophoblast 
subtypes form the interface between mother and fetus and exert a crucial role in 
implantation and placentation necessary for successful pregnancy. Several 
pathologies are related with excessive trophoblast invasion, such as placenta 
percreta or choriocarcinoma, or with shallow invasion such as preeclampsia. The 
major aim of this part of the thesis was to further investigate the involvement of 
PIM kinases in regulation of trophoblast behavior. This may help to understand 
not only the physiology of embryo implantation and placentation, but also to 
identify potential disorders, which may lead to pregnancy complications.  
In the human immortalized first trimester extravillous trophoblast cell line 
HTR8/SVneo and in the choriocarcinoma cell line JEG-3, we have analyzed the 
mRNA expression of PIM1, PIM2 and PIM3 by quantitative real time-PCR, and 
their protein expression by Western blotting and immunocytochemistry. We have 
further investigated the expression kinetics after stimulation with LIF. We have 
inhibited PIM kinases by using SGI-1776 at different doses for up to 3 days. 
Subsequently, we have studied the kinetics of cell viability by MTS assays and the 
proliferation by BrdU assays. Development of apoptosis was analyzed by Western 
blotting for BAD, BCL-XL, (cleaved) PARP and CASP3 as also the expression 
and phosphorylation of the potential PIM target c-MYC. Additionally, apoptosis 
and necrosis was tested by flow cytometry by annexin V and propidium iodide 
binding.
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The major results are that all analyzed PIM kinases are expressed in both 
cell lines and further increased upon stimulation with LIF. Inhibition of PIM kinases 
significantly reduces viability and proliferation and induces apoptosis as assessed 
by increased cleaved PARP and annexin V/propidium iodide binding. 
Simultaneously, phosphorylation of c-MYC was reduced.  
These results demonstrate the involvement of PIM kinases in LIF-induced 
regulation in two different trophoblastic cell lines which may indicate similar 
functions in primary cells.  
Part II  
Trophoblast cells have the ability to differentiate into embryonic lineages, 
which behave similar to tumor cells. In previous studies of our group, it has been 
demonstrated that trophoblast cells are able to form spheroids. We hypothesized that 
HTR8/SVneo-derived spheroids may have properties similar to cancer stem-like cells 
(CSCs). As per literature, formation of spheroids promotes proliferation, migration 
and invasion in tumors (or also in trophoblast cell lines). HTR8/SVneo cells were 
used as a model for the analysis of tumor-like behavior of trophoblast cells. Our aim 
was to study and characterize the cancer stem cell-like properties in spheroids 
formed from HTR8/SVneo cells and the effect of cytokines such as LIF and OSM 
upon stimulation. We have observed that the HTR8/SVneo cells forming spheroids 
expressed the stem cell surface marker CD44+ve high/CD34+ve low /CD24+ve low. Upon 
LIF stimulation these markers showed a decreased expression. The stemness-
related transcription factors NANOG and CDX2 were constitutively expressed. Upon 
OSM treatment the expression level of NANOG is increased and that of CDX2 
decreased. Hence, we conclude that HT8/SVneo cells contain a fraction or side-
population that expresses stemness related factors. Functions and capabilities of 
these cells remain to be investigated. 
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ZUSAMMENFASSUNG 
Teil I 
Die “Proviral Insertion in Murine (PIM) Lymphoma” Proteine bilden eine 
Serin/Threonin Kinase Familie bestehend aus drei Isoformen: PIM1, PIM2 and 
PIM3. Diese spielen eine entscheidende Rolle bei der Kontrolle der Zellviabilität, 
der Proliferation, des “Homing”, der Migration, der Apoptose und anderer 
Vorgänge. Die Überexpression von PIM Kinasen wurde in verschiedenen 
humanen Tumoren beobachtet, vorwiegend in hämatologischen. PIM Kinasen 
sind Zytokin-abhängig und werden vorwiegend durch Janus Kinase/Signal 
Transducer Activator of Transcription (JAK/STAT) Signalwege aktiviert. Diese 
werden vor allem von Zytokinen der Interleukin-6 (IL-6) Familie aktiviert, aber 
nicht ausschließlich. Auch Leukemia Inhibitory Factor (LIF) und Oncostatin M 
(OSM) gehören zu dieser Familie. Verschiedene Trophoblast-Subtypen formen 
die Grenzfläche zwischen Mutter und Fetus und spielen eine bedeutende Rolle in 
der Implantation und Plazentation und sind somit notwendig für eine erfolgreiche 
Schwangerschaft. Mehrere Pathologien sind assoziiert mit exzessiver 
Trophoblast-Invasion, so wie Placenta percreta or Chorioncarcinom, oder mit 
schwacher Invasion so wie Präeclampsie. Das Ziel dieses Teils der Arbeit war die 
weitere Untersuchung der Beteilung von PIM Kinasen an der Regulation des 
Verhaltens von trophoblastären Zellen. Die Ergebnisse können dazu beitragen, 
nicht nur die Physiologie der Embryo-Implantation and Placentation weiter zu 
verstehen, sondern auch potenzielle Störungen, die zu 
Schwangerschaftskomplikationen führen können. Wir haben die humane 
immortalisierte extravillöse Ersttrimester Trophoblast-Zelllinie HTR8/SVneo und 
die Chorioncarcinom-Zelllinie JEG-3 als Modelle benutzt. Die mRNA-Expression 
von PIM1, PIM2 und PIM3 wurde mittels quantitativer real time-PCR, und die 
Protein Expression mittels Western blotting und Immunozytochemie gemessen. 
Wir haben darüber hinaus die Expressionskinetik nach Stimulation mit LIF 
untersucht. Wir haben die PIM Kinasen mittels verschiedener Dosen SGI-1776 
bis zu 3 Tagen inhibiert. Anschließend haben wir die Kinetik der Zellviabilität 
mittels MTS Assays und die Proliferation mittels BrdU Assays untersucht. Das 
Fortschreiten der Apoptose wurde mittels Western blotting für BAD, BCL-XL, 
(gespaltenes) PARP und CASP3 analysiert sowie die Expression und 
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Phosphorylierung des potenziellen PIM Targets c-MYC. Zusätzlich wurden 
Apoptose und Nekrose durchflusszytometrisch durch Annexin V- und 
Propidiumiodid-Bindung bestimmt. 
Die wichtigsten Ergebnisse sind, dass alle analyzierten PIM Kinasen in 
beiden Zelllinien exprimiert werden, was durch Stimulation mit LIF weiter 
gesteigert wurde. Die Inhibierung der PIM Kinasen reduzierte signifikant die 
Viabilität und Proliferation der Zellen und induzierte signifikant die Apoptose, 
besonders deutlich durch den Anstieg an gespaltenem PARP sowie durch 
gesteigerte Annexin V und Propidiumiodid-Bindung. Gleichzeitig war die 
Phosphorylierung von c-MYC reduziert.  
Diese Ergebnisse demonstrieren die Beteiligung von PIM Kinasen an der 
LIF-induzierten Regulation in zwei verschiedenen trophoblastären Zelllinien, was 
auf ähnliche Funktionen in primären Zellen hindeutet.   
Teil II  
In früheren Studien unserer Gruppe konnten wir zeigen, dass 
Trophoblastzellen in der Lage sind Spheroide zu formen. Wir haben erwartet, dass 
HTR8/SVneo-Zell-Spheroide ähnliche Eigenschaften wie Tumor-Stammzellen 
entwickeln. In der Literatur wurde berichtet, dass die Bildung von Spheroiden die 
Proliferation, Migration und Invasion in Tumoren (oder auch in Trophoblastzelllinien) 
steigert. HTR8/SVneo-Zellen wurden von uns als Modell genutzt zur Untersuchung 
von tumor-ähnlichem Verhalten von Trophoblastzellen. Unser Ziel war, Tumor-
Stammzell-ähnliche Eigenschaften in aus HTR8/SVneo-Zellen geformten Spheroiden 
zu untersuchen und die Effekte der Zytokine LIF und OSM zu testen. Wir haben 
beobachtet, dass HTR8/SVneo-Zellen in Spheroiden die 
Stammzelloberflächenmarker CD44+ve high/CD34+ve low /CD24+ve low exprimieren. Nach 
Stimulation mit LIF zeigten diese Marker eine verminderte Expression. Die 
Stammzell-assoziierten Transkriptionsfaktoren NANOG und CDX2 wurden konstitutiv 
exprimiert. Nach Behandlung mit LIF stieg die Expression von NANOG und 
verminderte sich die Expression von CDX2. Wir schlussfolgern deswegen, dass 
HTR8/SVneo-Zellen eine Fraktion oder Neben-Population aufweisen, die Stammzell-
assoziierte Faktoren exprimiert. Die Funktionen und Fähigkeiten dieser Zellen sollten 
in späteren Studien untersucht werden.  
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CHAPTER 1 INTRODUCTION 
1.1 Pregnancy-An enigma of new life 
Pregnancy is a beautiful event of creation of new life on earth, which is accompanied 
by its own enigma towards its success and failure. So far, researchers are doing all 
the possible to unravel this mystery. 
It goes back in the times when a famous scholar in the field of reproduction biology 
named Medawar in 1953 put these words into the world of science to solve the need 
of understanding pregnancy and its complications  Billington (2003). 
Pregnancy has its own charm to pull anyone towards its riddle and create quest to 
unwind the story. In literature pregnancy is defined as the period taking place up to 
38-40 weeks from the time of its start.  
Pregnancy has been always viewed as a close cooperative interaction and regulation 
between a mother and her fetus. During implantation, fetal derived cells (trophoblast) 
invade the maternal endometrium and remodel the endometrial spiral arteries into 
low-resistance vessels that are unable to constrict (Haig 1993)  . 
Migratory interstitial cytotrophoblasts play a role in the preparation of the myometrium 
segments of the utero-placental arteries for the second wave of endovascular 
trophoblast migration that occurs in the second trimester of human pregnancy 
(Pijnenborg et al. 1983). 
 
Columns of trophoblast cells advance to the base of the implantation site where they 
spread out to form a cytotrophoblastic cell. In addition, cytotrophoblasts advance into 
the lumen of the spiral arteries. They are responsible for remodeling these vessels to 
form wide, low-resistance conduits. In human and great apes, there is additional 
invasion of the endometrium and its vessels by trophoblasts originating from the base 
of the anchoring villi. Deep trophoblast invasion that extends remodeling of the spiral 
arteries to segments in the inner myometrium evolved in the common ancestor of 
gorilla, chimpanzee and human (Carter et al. 2015). 
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1.2 Stages in Pregnancy 
During pregnancy, the woman undergoes many physiological changes including 
hematological, renal, metabolic, cardiovascular and respiratory.  Human pregnancy is 
divided into three stages or trimesters. The first twelve weeks of pregnancy are 
termed to be first trimester which includes fertilization of egg travelling down the 
fallopian tube and attachment, invasion of the blastocyst into the endometrium of the 
uterus. There, the embryo and placenta start their journey with several modifications 
in terms of immunological tolerance and building a favorable environment for their 
development (Duc-Goiran et al. 1999).  
There is a high risk of miscarriage during the first trimester. During first trimester, a 
large number of cells expressed by the decidua are leukocytes, among that the 
largest single population are natural killer cells with smaller numbers of macrophages 
and T cells (Hohn und Denker 2002). However by the end of pregnancy these NK 
cells are the smallest cell population left (Starkey et al. 1988). The second trimester 
is from week thirteen to twenty eight, where the movement of fetus can be felt by the 
mother. The third trimester is from week 29 to 40. 
 
1.3 Ovulation and Implantation  
After the woman’s last day of the menstrual period cycle, the uterus begins a 
proliferative phase until the rise of the follicle stimulation hormone (FSH) that 
subsequently leads to ovulation in order to give rise to mature oocyte. The fusion of 
this egg cell with a male gamete to form a zygote is called fertilization. This stage is 
also considered an event of initiation of the pregnancy. 
In humans implantation has been conceptualized as a stepwise process involving 
apposition and adherence of a blastocyst to the endometrium, followed by breaching 
of luminal epithelium and finally invasion into maternal tissues.  
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In order for implantation to happen, endometrium has to undergo changes and 
becomes decidua (Salamonsen et al. 2003), which is accomplished by the 
modification of endometrial stromal cells, uterine vessels and glands as well as 
immune cells (Lunghi et al. 2007). From (Figure.1) it is shown after fertilization, the 
embryo develops from morula to blastocyst (after day 5), a spherical structure 
composed of cells called inner cell mass (ICM), and outside of it is trophoblast cells. 
The ICM subsequently develops into the fetus.  
Implantation starts after the hatching of the blastocyst to the zona pellucida (day 6). 
window of implantation (WOI), is characterized by two situations: 1. Endometrium 
receptivity (Duc-Goiran et al. 1999), 2. Blastocyst invasion competence as a result it 
breaches the uterine epithelium (day 7).  The first cell-to-cell contact can be 
recognized when apical plasma membranes of trophoblast and uterine epithelial cells 
adhere (Hohn und Denker 2002) (Poehlmann et al. 2005a). The expression of 
adhesion molecules such as integrin’s, adherins, selectin and immunoglobulin 
superfamily, is involved in this process. 
The ICM begins to differentiate into different layers and begins to produce human 
chorionic gonadotropin (HCG), a hormone that insures the implanting embryo. The 
trophoblast mediates the attachment and invasion into the uterine wall over next few 
weeks. Thereby, placenta develops and continues production of progesterone 
initiated by corpus luteum that controls and maintains decidualization. The decidua is 
the uterine basis of the mother guaranteeing that the fetus is provided with nutrient 
and oxygen needed for its successful growth and development. (Norwitz 2006) 
(Damjanov 2014).  Progesteron has been implicated in immunosuppression at the 
feto-maternal interface, hence protecting the fetus from unwanted immunological 
response. Due to higher secretion of progesterone from the corpus luteum (CL), the 
secretory phase replaces proliferative phase in order to prepare the endometrium for 
implantation by stimulating endometrial glands (Lee et al. 2011a) (Szekeres-Bartho et 
al. 2009) (Santoro et al. 2000). Implantation is regulated by a complex interplay 
between endometrium and trophoblast.  
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The endometrium controls the trophoblast invasion by secreting cytokines and 
protease inhibitors, which in turn modulate the invasion of trophoblast. Less HCG is 
produced due to the closer presence of trophoblast to the endometrium, allowing 
further differentiation of trophoblast into anchoring type cells.  Decidualization 
continues and regulates the placental formation and the expression of regulatory 
factors such as surface antigens, metalloproteases and major histocompatibility 
(MHC) molecules (Hess et al. 2007). Decidua basalis is characterized by infiltration of 
immune-competent subsets cells like natural killer cells (NK) cells, progenitor cells, 
some T cells (Trundley und Moffett 2004), macrophages and a few B cells. Decidua 
in simple terms may be capable of inducing an immunological reaction against the 
implanting blastocyst, or later placenta.  These cells produce a respective cytokine 
profile regulating implantation and trophoblast invasion (Saito 2000).  
Ovulation 
Fertilization 
Zona pellucida 
Day 7  
Day 6  
Day 5  
Day 2-3  
Day 4  
Day 1  
Implantation 
 
 
Figure 1. Ovulation and implantation.  
Fertilization occurs in the fallopian tube within 24 to 48 h of ovulation. The initial stages of 
development, from fertilized ovum (zygote) to a solid mass of cells (morula), occur as the 
embryo passes through the fallopian tube encased within a non-adhesive protective shell 
(the zona pellucida). Modified (Red-Horse et al. 2004) 
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1.4 Placentation 
Placenta is an organ that is transient and depicted as a simple disc-shaped structure   
which is rapidly assembled in the extra-embryonic compartment (Hunkapiller und 
Fisher 2008). Humans have a hemochorial placenta, where blood from mother 
comes in direct contact with fetal derived trophoblast cells. Chorionic villi are sprout in 
order to give a maximum possible area of contact within the maternal blood, thus 
these villi are the interface between mother and fetus. Placenta cells produce several 
peptide and steroid hormones (Tuckey 2005), cytokines, growth factors and other 
bioactive factors. Placental functions can be viewed as different aspects of protection 
such as against dehydration, toxic metabolites, malnutrition (Evain-Brion und 
Malassine 2003) (Myllynen et al. 2005).  
 
Figure 2. The human placenta.  
Villous trophoblasts of the human placenta grow as a branched structure, maximizing 
exchange with maternal blood. Extra villous trophoblast invades into the maternal 
endometrium Modified (Frost und Moore 2010). 
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Trophoblast cells are embryonic tissue formed during early stage of pregnancy 
deriving from the “trophoectoderm” (Figure.2). They form the outer layer of the 
blastocyst, providing the nutrients to the embryo and further develop into large part of 
placenta (Haig 1993). Trophoblast further proliferates and differentiates into two 
layers. 1). Cytotrophoblast (CTB): Single celled, inner layer of the trophoblast 
(Bischof und Irminger-Finger 2005), which further develops into extra-villous 
trophoblast cells (EVT) formed from the tip of the villi, growing out from placenta, 
penetrating the decidualized uterus (Handwerger 2010) and 2). Syncytiotrophoblast 
(STB) a multinucleated cell complex (Mi et al. 2000) (Fisher et al. 1989) that divides 
maternal and fetal blood streams in gestation, also secreting human chorionic 
gonadotropin (HCG) (Soncin et al. 2015) (Faas et al. 2014). STB is formed by the 
fusion of cytotrophoblasts and is responsible for initiation of invasion of endometrium 
(Faas et al. 2014). (Fig 3) The deeper penetration of maternal tissues is achieved by 
cytotrophoblasts. Both cells resemble to each other and can be identified 
histochemically (Haig 1993). One of the modulating mechanisms during villous 
branching is by the human placental macrophage (Hofbauer cell) (Anteby et al. 
2005). The arterioles that supply blood to the endometrium becomes highly coiled are 
known as spiral arteries (Fig 4). They transport the maternal blood to the placenta. 
The maternal tissues that line the uterus are called decidua. They shed with the 
placenta during delivery (Haig 1993).  The hemochorial placentation (Fig 5 ) which 
requires an epithelial-to-endothelial conversion (Iruela-Arispe 1997) and it arises 
primarily through differentiation, proliferation, migration and invasion of the 
endometrium and its vasculature by the CTB (Duc-Goiran et al. 1999). Similarities 
have been frequently asserted between growing fetus and invading cancer (Quenby 
und Brosens 2013) (Pollheimer und Knofler 2005) (Koldovsky 1999) in terms of 
invasion, migration and proliferation. Malign cells have similarities with CTB and EVT, 
which show highly invasive characteristics especially during implantation and first 
trimester of pregnancy: There is involvement of autocrine/paracrine communications, 
adhesion molecules and protease profiles.  In healthy pregnancy the invasive growth 
by EVT is restricted to the uterus of the first trimester (Lunghi et al. 2007). EVT cells 
enter the decidua and subsequently later the myometrial stroma as interstitial 
trophoblast (Brosens et al. 2002). 
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There they form giant cells and lose invasiveness. EVT also surround and destroy 
smooth muscle cells (SMC) of spiral arteries hence replacing the fibroid material. 
Further, EVT invade the lumen of the arteries to replace the endothelium of the 
vessels (Zhou et al. 1997). MHC class I molecules are expressed in EVT cells, in 
particular human leukocyte antigen HLA-C, E and G which are good ligands for many 
killer immunoglobulin receptors (KIR) present on NK cells. Such interactions modify 
the cytokine receptors and regulate adhesion molecules as well as Matrix Metallo 
Proteinases (MMP) (Matthiesen et al. 2005). MMPs, α5β1 integrin’s, VE-cadherin’s 
and trophoblast specific HLA class I (e.g. HLA-G) support EVT invasion. Although the 
invasiveness of the trophoblast is known to be regulated in local and temporal terms, 
the regulation of these activities is also related to differentiation pathways leading to 
formation of non-invasive villous trophoblast serving endocrine as well as nutritive 
functions (Hohn und Denker 2002).  
 
Figure 3. Placental chronic villi  
Stem from the chorionic plate and lie within the intervillous space. The point of attachment 
between anchoring villi and the underlying tissue is the basal plate (box B).  Enlargement of 
the area in box. Undifferentiated CTB in the anchoring villi give rise to invasive CTBs that 
invade the uterine interstitium (interstitial invasion) and the maternal endothelium 
(endovascular invasion). Modified (Hunkapiller und Fisher 2008) 
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Figure 4. Spiral artery remodeling  
Maternal spiral artery remodeling through the combined action of interstitial and 
endovascular extravillous trophoblast cells. EVT cells invade uterine wall and maternal spiral 
arteries replacing smooth muscle with fibroid material and part of vessel endothelium, thus 
evoking artery dilatation. Decidual immune cells, like macrophages and NK cells facilitate 
deep invasion of EVT cells up to myometrial portions of spiral arteries. Modified (Lunghi et al. 
2007). 
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Figure 5. Hemochorial Placentation 
Schematic diagram showing structures within human hemochorial placentation sites. 
Modified (Soares et al. 2012) 
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1.5 Soluble factors involved in pregnancy: hormones, growth 
factors, cytokines 
A large number of hormones, growth factors and cytokines (Figure 6) are produced 
by both the pre-implantation embryo and the maternal endometrium: hormones like 
HCG, progesterone, growth factors like TGF, cytokines and receptors (Duc-Goiran et 
al. 1999).  Pregnancy hormones are important for maintenance of the corpus luteus 
acting on luteotropic hormone that stimulates the production of progesterone via 
luteinizing hormone-receptors (LHR).  Estrogen regulates uNK cells in the 
decidualization process, which helps the fetus to attach to the endometrium (Gibson 
et al. 2015). Human placental growth hormone (hPGH) and hPlacental lactogen 
(hPL) are released into both maternal and fetal circulation. They are found in the 
syncytiotrophoblast layer of placenta helping in stimulating the insulin-like growth 
factor (IGF) production and modulating metabolism, resulting in increased availability 
of glucose and amino acid to the fetus (Handwerger und Freemark 2000).  
Growth factor expression/secretion is stimulated by paracrine interactions of diverse 
maternal and placental cell types. Predominant growth factors of the fetal-maternal 
interface as well as their mutual stimulations are shown in below Figure 6. During the 
early stage of blastocyst, epidermal growth factor (EGF) and transforming growth 
factor (TGF) are co-expressed with EGF-receptors (EGF-R) suggesting an autocrine 
function in human development. Platelet-derived growth factor (PDGF) with its two 
receptor subunits, α and β is expressed from 8-cell stage onwards, while blastocyst 
secrets IGF factor II (IGF-II) (Srivastava et al. 2013).  With the exception of TGFβ all 
factors depicted were shown to positively influence trophoblast proliferation and/or 
migration/invasion. Some soluble ligands such as HCG may play key roles in 
trophoblast motility since several growth factors trigger their secretion and also 
promote trophoblast migration through elevation of VEGF and LIF secretion. Hence, 
when studying effects of a particular growth factor on trophoblast migration direct as 
well as indirect effects must be considered.  Colony stimulating factor I (CSF-I), 
similar to EGF and TGF, promotes EVT proliferation and stimulates production of 
MMPs and TIMPs in EVT.  VEGF is synthesized by decidua macrophages and 
promotes EVT cell proliferation. 
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Cytokines are small multifunctional proteins often derived from leukocytes and have 
primarily been described through their immunomodulatory actions. The maternal–
fetal interface is considered to be immunosuppressed to allow development of the 
semi-allogeneic placental fetal unit. However, cytokine profiles of the decidua and 
different decidual cell types suggest that the situation in vivo might be more complex 
than in vitro. Cytokines do not only play a role in immunoregulation, but also in other 
aspects of the establishment of pregnancy, including the regulation of trophoblast 
invasion and spiral artery remodeling. Dysregulation of decidua-derived cytokines 
may be involved in the etiology of unexplained spontaneous miscarriage (Lash und 
Ernerudh 2015).  Cytokines are regulated at the transcriptional and translational 
level, usually leading to an altered proliferation, and differentiation in the target cell. 
(Table 1) One of the main functions of cytokines is regulation of inflammation, 
typically mediated by Th1 type (pro inflammatory) and Th2 type (anti-inflammatory). 
Representative Th1 type cytokines are interleukin 2 (IL-2) or interferon (IFN) γ. Th2 
type cytokines are IL-4, IL-10, IL-13 and others. 
 
Table 1. Summary of some assorted cytokine profiles during pregnancy 
Name Function 
TNF- α (Toder et al. 2003)  Activates intercellular signaling in embryonic 
development 
IFN- γ (Resch et al. 2004)  Release of prostaglandins 
IL-1 (Prutsch et al. 2012)  Interacts with endometrial glandular epithelial 
cells, trophoblast cell motility 
IL-6 (Prins et al. 2012)  Expressed in endometrial stromal cells and 
involved in pro-inflammatory reactions, 
supports trophoblast invasion 
IL-8 (Jovanovic et al. 2010)  Trophoblast cell migration and invasion 
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B	A	
 
Figure 6. Cytokines, Hormones and Growth factors. 
Interplay between growth factors expressed at the fetal-maternal interface. Stimulating 
(arrows) as well as inhibitory effects on expression / secretion are depicted. Modified (Knofler 
2010). B. Cytokines in embryo growth and development (Yessoufou und Moutairou 2011). 
 
1.6 LIF in pregnancy  
Leukemia Inhibitory factor (LIF), is a secreted multifunctional glycoprotein belonging 
to the IL-6 super family, regulating various cellular function via binding to the 
membrane bound ligand receptor of LIF-receptor (LIFR) and gp130 (Mathieu et al. 
2012). Its production is unregulated by progesterone and IL-4, and down regulated 
by various inflammatory mediators like IFN-γ. Successful embryo implantation 
depends on an ideal cross talk between embryo and receptive endometrium which 
includes bilateral secretion and reception of LIF. It is produced by endometrium and 
blastocyst regulates growth and development of the embryo, There are three splice 
variants of LIF, which include diffusible, membrane-associated and truncated forms 
acting in paracrine fashion (Aghajanova 2004). Throughout the period of 
implantation, ovarian steroids regulate the expression of LIF, LIFR and gp130 in 
utero (Sherwin et al. 2004). In human, TGF-β and HCG increase LIF secretion by 
endometrial epithelial cells form follicular and secretory phase during menstrual cycle 
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(Perrier d'Hauterive et al. 2004).  LIF stimulates stromal decidualization by increasing 
the production of cytokines and prostaglandins.  
LIF is also involved in enhancing embryo-endometrial interaction through pinopodes 
and adhesion molecules by stimulating trophoblast cell differentiation and increasing 
trophoblast capability to invade the uterine stroma. LIF acts as a pro-inflammatory 
cytokine and its decrease is involved in recurrent miscarriages’ (Bischof und 
Irminger-Finger 2005) (Bischof und Irminger-Finger 2005). Noteworthy, LIF plays vital 
role in recruitment of a specific cohort of leucocytes which participates in 
inflammatory response during implantation. There are numerous factors (Figure 7) 
which are influenced due to the presence and absence of LIF during embryo and 
endometrial interaction, such as: heparin binding-epidermal growth factor (HB-EGF), 
epiregulin, amphiregulin, estrogen, progesterone, interleukins (e.g. IL-5, IL-6), 
prostaglandins (e.g. E2), cyclooxygenase (Lee et al. 2011b), NK cells, peroxisome 
proliferator-activated receptor, HCG or mucin (which is a glycocalyx expressed at the 
apical membrane of luminal epithelial and its expression is reduced during 
trophoblast invasion) (Sharma und Kumar 2012), junctional adhesion molecules (Su 
et al. 2012), Matrix metalloproteins (MMPs) and Tissue inhibitory proteins (TIMPs) 
(Wang et al. 2002a);(Song et al. 2000);(Salleh und Giribabu 2014) as shown in 
(Figure 7).  
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Figure 7. Summary of the known roles of LIF in embryo implantation. 
LIF increases the expression of implantation genes in receptive endometrium. Modified 
(Salleh und Giribabu 2014). 
 
1.7 Signaling network-mechanism  
During human pregnancy, implantation and invasion of placental trophoblast into 
uterine wall is an essential event which is remarkable, flexibility of the trophoblast in 
fulfilling various functions such as secretions of hormones, anchorage of the 
placenta, modulating the decidual angiogenesis/ morphogenesis and spiral artery 
remodeling of maternal tissues, which requires increase blood flow (Knofler 2010).  
These processes are mediated by a complex network of signaling and adhesive 
factors (Massuto et al. 2010). Several extracellular stimuli (Table 2) initiate 
intracellular signal transduction upon interaction with receptor tyrosine kinase (RTKs), 
G-coupled receptors (GPCRs) and others, which ultimately leads to the activation of 
critical signaling cascades.  
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Table 2. Summary of signaling pathways in human 
 (Soncin et al. 2015); (Knofler 2010); (Gundogan et al. 2011); (Busch et al. 2009). 
Signaling factor Cell/Tissue Type  Function 
FAK First trimester CTB Increased differentiation into EVT 
HGF/c trophoblast Promotes EVT migration 
Notch First trimester CTB and explants  Variable effects (ECM-dependent) 
PKA Term CTB Promotes STB differentiation 
PI3K/Akt Third trimester cell line Promotes EVT migration 
PPARγ First trimester and term CTB Inhibit invasion of EVT, promotes 
STB differentiation 
Wnt Choriocarcinoma cell line, first trimester 
CTB 
Promote cell-cell fusion and 
stimulates migration/invasion of 
EVT 
Activin/Nodal First trimester Inhibits cell invasion, proliferation 
and differentiation of EVT 
anchoring, induce apoptosis 
mTOR Immortalized first trimester trophoblast 
cell 
Mediates trophoblast invasion 
through MMP 
 
To understand the molecular networks involved in regulating an immune response, 
the cytokine receptor signaling and transduction pathways have been extensively 
studied and reported. Cytokines are regulators of embryogenesis and participate in 
inflammation triggering the onset of labor in late pregnancy (Orsi 2008). The Janus 
kinase/signal transducer activator of transcription (JAK/STAT) signaling network 
provides a very fast intracellular signal from a receptor to the nucleus.  JAK/STAT 
consist of three main components: 1. Receptors, 2. Janus kinases, 3. STATs. The 
receptors are triggered by growth factors, interferon, interleukins and other chemical 
messengers which thereby, further activates JAK upon auto phosphorylation (SH2 
domain binding) which then activates the STATs (SH2-domain possessing protein 
binds to the phosphorylated receptor, in turn STAT becomes phosphorylated 
(Aaronson und Horvath 2002). STATs are described as ligand-induced transcription 
factors (Darnell et al. 1994);(Darnell 1997);(Murray 2007).  
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Encoding genes and alternative post translational proteolytic cleavage generate 
additional forms (Jatiani et al. 2010) of STAT1, STAT2, STAT3 (Schaefer et al. 
1995), STAT4 (STAT-4α and STAT-4β) and STAT5 (STAT-5a and STAT-5b) (Lin et 
al. 1996). EVT cells resemble tumor in their invasive and destructive properties, 
mainly during first trimester of pregnancy. LIF provides an extracellular signal 
stimulating invasion in trophoblast cells and induces STAT3 DNA binding activity in 
choriocarcinoma cells. STAT3 phosphorylation correlates with trophoblast 
invasiveness (Corvinus et al. 2003); (Poehlmann et al. 2005a). IL-11 activates STAT3 
in choriocarcinoma cells and increases invasion (Suman et al. 2009). STAT3 
activation induces expression of suppressors of cytokine signaling (SOCS3). Its 
absence is lethal to the embryo due development of placental insufficiency, hence 
SOCS3 seems to be important for pregnancy by regulating LIF-driven trophoblast 
differentiation (Fitzgerald et al. 2009). STAT3 activation is sustained by IL-10 
expression in trophoblast cells resulting in increased cell motility (Dallagi et al. 2015). 
1.8 Pathologies in pregnancy 
To achieve successful pregnancy, it requires well-coordinated implantation of the 
embryo into the receptive decidua, placentation, trophoblast invasion of the maternal 
decidua and myometrium in addition to remodeling of the uterine spiral arteries. 
Failure of any of these steps can lead to a range of pregnancy complications, 
including miscarriage, infertility, pre-eclampsia, inter-uterine growth restriction 
(IUGR), placenta accrete, placenta previa, pre-term birth (PTB), pre-term labor (PTL) 
(Lash und Ernerudh 2015) or choriocarcinoma.  Recurrent pregnancy loss (RPL) 
(Shahine und Lathi 2015); (Gammill et al. 2015) is a multifactorial condition of 3 or 
more consecutive pregnancy losses that affects 1-5% couples. Infertility is a very 
common complication defined as the inability to establish successful pregnancy 
within a certain period of time. Preterm birth is defined as before 37th week of 
pregnancy, which in worse cases may cause neonatal death or long term handicaps 
infants (Simons und Schatz 2012), It may be induced by insufficient trophoblast 
invasion (Hoesli et al. 2002).  IUGR is a complicated disorder with varying etiology in 
pregnancy, characterized by failure of the embryo to accomplish its normal growth, 
hence resulting in morbidity and cardiovascular disease in adult life, it is mainly 
associated with placental dysfunction (Gourvas et al. 2012).  
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Preeclampsia is defined as high blood pressure, proteinuria and inflammation with an 
onset in the second half of pregnancy, it may occur as a  result of abnormal 
placentation (Figure 8)  due to loss of trophoblast differentiation. It has a high 
incidence in developed countries (Scioscia et al. 2015); (Sifakis et al. 2015). 
Choriocarcinoma is a rare but an aggressive and destructive malignant form of 
trophoblastic neoplasm that is associated with distant metastasis (Emin et al. 2015); 
(Froeling und Seckl 2014), it arises from hydatidiform mole, hyperplasia of 
trophoblast and villous cistern formation (Feist et al. 2015), although choriocarcinoma 
is not common in Europe or US but its prevalence is found ten times higher in Asian, 
African and south American countries. All gestational trophoblastic diseases (GTD) 
produce HCG, which often serves as diagnostic tool being a good parameter for 
progress of the disease or success of therapy (Khoo 2003). 
 
Figure 8. Pathology during pregnancy 
Trophoblast invasion into the spiral arteries in the placental bed in normal pregnancy and in 
preeclampsia, modified (VanWijk et al. 2000). 
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1.9 PIM kinases  
Proviral insertion sites in moloney murine leukemia virus or PIM genes were 
identified as oncogenes in mid 1980s nearly three decades ago. PIM proteins 
belonging to serine/threonine kinases family consist of three different isoforms (PIM1, 
PIM2 and PIM3) and are highly evolutionary conserved (Narlik-Grassow et al. 2014); 
(Nawijn et al. 2011).  
1.10 Structure and Function 
The three isoforms of PIM kinases (PIM1, PIM2,PIM3) (Figure 9) (Nawijn et al. 2011). 
PIM genes are located at different chromosomal locations in humans. PIM mRNA 
has short half-life span owning to the presence of multiple copies of the destabilizing 
3’ untranslated region (UTR) (Feldman et al. 1998). Human PIM1 and PIM2 have 
alternative translational sites, resulting in the presence of two (PIM1) and three 
(PIM2) protein isoforms; the subcellular localization and substrate interactions are 
isoform specific. PIM1 and PIM3 share high degree of homology and 71% are 
identical at the amino acid level, PIM1 and PIM2 are 61% identical (Nawijn et al. 
2011). PIM1 kinase encodes 33 and 44 kDa isoforms that have comparable kinase 
activity (Saris et al. 1991).  
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ATG
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34 kD
ATG
CTG
Kinase domain
Pre-B cell lymphomas
Hyperplastic growth and 
transformation of large pre-B 
cells owing to the accumulation 
of mutations that affect their 
ability to keep pre-B cell 
receptor and MYC levels at 
bay.
Kozak sequence
The consensus gccRccAUGG (R 
represents a purine) sequence 
in the 5  region of eukaryotic 
mRNA that is the optimal 
ribosomal-binding site and 
facilitates initiation of 
translation.
Primary response gene 
PRG. Upon mitogenic stimuli, 
upregulation of PRG 
transcription is rapid but 
transient and does not require 
de novo protein synthesis. 
Most PRGs are transcription 
factors and propagate 
signalling by regulating 
expression of a cascade of 
downstream secondary target 
genes.
For example, tumour outgrowth is substantially accelerated 
in Eμ–Pim1 mice carrying two copies of this transgene, 
and Pim1-transgenic mice carrying an optimized Kozak 
sequence to promote efficient Pim1 expression could 
not be maintained as a transgenic line because the mice 
succumb d to lymphomas before they could reproduc  
(A.B., unpublished observations).
The strong dependency of MYC-induced lympho-
mas on the expression of Pim family kinases was further 
illustrated by MuLV insertional mutagenesis (FIG. 2) in 
Pim1-deficient Eμ–Myc-transgenic mice, in which pro-
viral activation of Pim2 occurred in 90% of the tumours 
and tumour latency was prolonged9,10. Moreover, inser-
tional mutagenesis on a Pim1;Pim2-deficient back-
ground resulted in the proviral activation of Pim3, a 
gene not previously found to be provirally activated in 
a Pim1- or Pim2-proficient background9, emphasizing the 
strong selective advantage associated with the activation 
of genes that can substitute for Pim1 and Pim2.
Regulation of Pim kinase activity
Pim kinases are constitutively active11,12, and the induc-
tion of PIM kinase activity is largely regulated at the 
transcriptional and translational levels. The signals that 
induce PIM gene expression are diverse, and cell type 
dependent. Normally, Pim kinases are broadly expressed 
in haematopoietic13–15, neuronal16,17, vascular smooth 
muscle18, cardiomyocyte19, endothelial20 and epithelial 
cell lineages21,22, as well as in early progenitors of some 
of these cells types23,24, and in embryonic stem (ES) 
cells14,20,25.
Regulation of Pim gene expression and translation. 
Pim genes generally display characteristics of primary 
response genes (PRGs) that are induced by the ac iv tion 
of transcription factors downstream of growth factor sig-
nalling pathways, such as the Janus kinase and signal 
transducer and activator of transcription (Jak–STAT) 
pathway26–30 and nuclear factor-κB (NF-κB; also known 
as NFKB1)31,32. Of special interest for the role of Pim 
kinases in solid tum ur  is the recent observation that 
hypoxia induces PIM1 expression, in a hypoxia-inducible 
factor1α (HIF1α)-independent manner33,34. Finally, one 
study reported that Krüppel-like factor 5 (KLF5) induces 
PIM1 expression upon DNA damage, thereby protecting 
cells from apoptosis35.
Pim mRNA transcripts have a short half-life owing 
to the presence of multiple copies of the destabiliz-
ing AUUU(A) sequence in the 3  untranslated region 
(UTR)15,36 (FIG. 1). The dominant effect of the 3  UTR on 
PIM protein levels is reflected by the proviral activation 
 At  a glance
•  Pim kinases are frequently overexpressed in human haematological malignancies and 
solid cancers, and they are often associated with strongly elevated MYC levels.
•  Overexpression of Pim kinases is associated with a good prognosis in some solid 
cancers, such as prostate cancer, but is associated with a poor prognosis in other  
solid cancers and most haematological malignancies.
•  Pim kinases are serine/threonine kinases that have consititutive activity (and therefore 
lack the need for post-translational activation). As their mRNA and proteins have a 
very short half-life, the activity of Pim kinases is largely regulated at the transcriptional 
and translational levels.
•  Pim kinases mediate survival signalling through phosphorylation of BCL-2-associated 
agonist of cell death (BAD), which induces release of the anti-apoptotic BCL-2 and 
BCL-2-like 1 (also known as BCL-X) proteins and thus lowers the threshold for 
apoptosis. Pim kinases might also induce BAD activities towards the regulation of 
glucose metabolism.
•  PIM2 can regulate cap-dependent translation in a mammalian target of rapamycin 
complex 1 (mTORC1)-independent manner, and in parallel to the PI3K–Akt pathway. 
This activity has been found to be relevant for certain human haematological 
malignancies, and is not shared with PIM1 or PIM3.
•  PIM1 can bind to MYC–MAX complexes and phosphorylate H3S10 at E-boxes, thereby 
setting off a cascade of events that leads to transcriptional pause release of RNA 
polymerase II at MYC-driven promoters. It remains unknown whether this activity 
contributes to tumorigenesis in vivo or whether other Pim family members share this 
activity with PIM1.
•  Pim kinases are promising targets for pharmacological inhibition, as the structural 
conformation of the ATP-binding pocket in the active site is different from that of 
other protein kinases, which in theory should allow the design of specific and 
selective inhibitors. The lack of any overt phenotypes in Pim1–/–;Pim2–/–;Pim3–/– mice 
indicates that such drugs might have a low toxicity profile.
Figure 1 | Pim genes, transcripts and proteins. Pim genes are located at different chromosomal locations in themous  
and human genome, as indicated by black numbers and numbers in orange boxes, respectively. Pim mRNA transcripts are 
encoded by 6 exons (dark blue boxes) with large 5  and 3  untranslated regions (UTRs; white boxes) containing a G/C-rich 
region (light blue lariat) and five copies of AUUUA destabilizing motifs ( orange circles), respectively15. Different protein 
isoforms are synthesized using alternative translation initiation sites (solid and dashed arrows) and additional codons 
present at the 5  of these mRNAs are depicted as light blue boxes. PIM protein isoforms have different molecular masses 
but retain their serine/threonine kinase activity43. Pim kinases have no regulatory domains and their highly conserved 
kinase domain is indicated by a white box. The Pim family of serine/threonine kinases has a high degree of homology — 
PIM1 and PIM3 are 71% identical at the amino acid level, and PIM1 and PIM2 are 61% identical (not shown)15.
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Figure 9. Structur of PIM Kinases 
PIM1, PIM2 and PIM3, modified (Nawijn et al. 2011) 
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The larger isoform localizes to the plasma membrane whereas the shorter isoform is 
primarily localized in the nucleus (Xie et al. 2006). PIM1 is highly expressed in 
hematopoietic, gastric, head and neck tumors (Bachmann et al. 2006).  PIM2 has 
three isoforms (34, 37, and 40 kDa), with no protein functions or interaction reported 
so far and is highly expressed in lymphoid and brain tissues (Cohen et al. 2004). 
PIM3 kinase has only one isoform (Nawijn et al. 2011) and is highly expressed in 
kidney, breast and brain tissues.  
1.11 Signaling pathways mechanism 
PIM kinases are mainly responsible for cell cycle regulation, anti-apoptotic activity 
and the homing and migration of receptor tyrosine kinases mediated via the cytokine 
dependent JAK/STAT pathway (Blanco-Aparicio und Carnero 2013) and NFKB (Zhu 
et al. 2002). PIM kinase gene expression is described in many cell types such as in 
neuronal, hematopoietic, endothelial, vascular smooth muscle, epithelial cell lineages 
(Gapter et al. 2006), cardiomyocytes, as well as in early progenitors cells (Cottage et 
al. 2010) and embryonic stem cells (Fischer et al. 2011); (Cottage et al. 2012).  The 
PIM kinase gene expression is largely regulated at the transcriptional and 
translational level. PIM kinases act downstream of multiple oncogenic tyrosine 
receptors, Janus kinase (JAK) (Wernig et al. 2008) and FMS-like tyrosine 3(FLT3) 
(Kim et al. 2005). JAK/STAT pathways play a critical role in regulation of the 
expression of PIM genes and represent alternatives to the secondary messenger 
signaling.  When cytokines bind to a cell membrane receptor, JAKs phosphorylate 
the receptor domain in the cytoplasm, creating an intracellular binding site for STATs 
which in turn bind to phosphorylated JAK, leading to STAT dimer formation and 
translocation into the nucleus, where STATs induce transcription.STAT3 specifically 
binds to promoter sequences of PIM1, enhancing its transcription and expression in 
response to a variety of cell mitogens such as interleukins and growth factors. 
Interestingly, PIM activates SOCS proteins and functions as part of negative 
feedback mechanism that serves to restraint JAK/STAT network (Peltola et al. 2004). 
At the translational level the expression of PIM kinases is mainly regulated by the 
stability of mRNA. PIM mRNA transcripts have very short half-life as mentioned 
earlier and due to which the AUUU(Haig 1993)  sequence located in the 3’ UTR is 
destabilized. 
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The regulation of protein stability is critical for the cellular function and activity. to PIM 
kinases have a  short half-life (less than 5min),  (Figure 10) their stability is mainly 
controlled through ubiquitination and proteosomal degradation while binding to heat 
shock protein (HSP70 and HSP 90) regulates PIM stability (Mizuno et al. 2001) ; 
(Shay et al. 2005). The initiation and progression of human cancer is linked to 
uncontrolled activation of survival kinases and two such pro-survival kinases that are 
commonly amplified in cancer are Akt (Protein kinase B /PKB) and PIM. So we are 
going to illustrate about PIM regulation with respect to cancer. PIM are oncogenic 
and have multiple functions (Narlik-Grassow et al. 2012). Altogether, these above 
mentioned studies show that PIM kinases may be constitutively active in cells and 
their activity can be influenced by phosphorylation by themselves or by other kinases. 
SOCS1 stability is regulated by PIM kinases by inducing JAK/STAT pathways and 
transcription of PIM kinases as induced by T cell antigen cross linking and cytokines 
such as IL-4, IL-6 and IFN-γ (Chen et al. 2002). 
 
 
Figure 10. Regulation of PIM Kinases  
mRNA and protein level in the presence of cytokines modified (Warfel und Kraft 2015). 
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1.12 PIM kinases in Cancer 
PIM kinases play important roles in regulating tumor cell proliferation by influencing 
cell cycle progression via p21 (Zhang et al. 2007), p27 (Wang et al. 2002b), p53 
(Hogan et al. 2008) and CDC25C (Bachmann et al. 2006). One of the primary 
machineries of survival and apoptosis for PIM kinases is elicited through their pro-
survival effect via the Bcl-2 family members, that has both pro-apoptotic (BAD and 
BAX) and anti-apoptotic (BCL-2 and BCL-XL) effects, where PIM kinases 
phosphorylate the BAD at ser 112, which disrupts the association with BCL-2, 
promoting binding and retention in the cytosol (Yan et al. 2003), hence resulting in 
anti-apoptotic activity. PIM kinases also inhibit the activation of CASP 3 and 9 (Chen 
et al. 2009b) (Chen et al. 2009a). The expression of PIM kinases in cancer is 
sufficient and converges to control the mTOR signaling pathway axis via upstream 
and downstream effectors (Sengupta et al. 2010); (Beharry et al. 2011).                                  
All the three isoforms of PIM kinases were reported to be genes co-activated with 
myc in murine lymphoid tumors (Nawijn et al. 2011). Overexpression of PIM kinases 
has been reported in a variety of human tumors. PIM1 expression is correlated to 
aggressive tumors and despite its frequent presence in human cancers, it is 
considered as weak oncogene. Studies in mice have shown though the incidence of 
tumor is evident but the oncogenic activity is low. However, the expression of PIM 
kinases is found to be enhanced in human prostate cancer cell lines (Kim et al. 
2010). The most interesting evidence supporting the cooperative property of PIM 
kinases is explained by their synergism with c-MYC. MYC is a proto-oncogene, which 
upon overexpression results in apoptosis in normal cells. PIM kinases contribute to 
tumorigenesis by enhancing MYC regulated signaling pathways. PIM kinases are 
most evident in myeloid leukemia like acute myeloid leukemia (AML) (Natarajan et al. 
2013). PIM is reported to mediate several B cell tumors, including B cell non-
Hodgkin’s lymphoma (NHL), Burkits lymphoma and multiple myeloma. PIM2 
overexpression leads to progression of tumor (Hiasa et al. 2015), PIM and PIM3 
kinase are increased in lymphoproliferative diseases associated with Epstein bar 
virus (EBV). Microarray analyses and immunohistochemical reports have shown that 
PIM isoforms are elevated in several tumors, including pancreatic (Li und Mukaida 
2014), gastric (Yan et al. 2012), renal (Mahalingam et al. 2011), hepatocarcinoma 
(Leung et al. 2015); (Endo et al. 2007) and colon cancers (Peng et al. 2013).  
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The PIM1/STAT3 signaling pathway plays a critical role in endothelial differentiation 
(Iwakura et al. 2011). 
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Figure 11. Schematic representation of PIM kinases in cell survival and apoptosis. 
 
1.13 Stem cells 
Discovery of stem cells was a team effort in 1963. Later in the 1980s the research 
was coined and from there on, it has been a boom to the world of science aiming to 
solve many diseases and pathologies (Thomson et al. 1998). Stem cells is the 
undeveloped or undifferentiated biological cell, that can differentiate and divide 
(mitosis) into new specialized cells which possess the ability of unlimited proliferation, 
self-renewal and generation of new tissues. The two main types of stem cells are 1. 
Embryonic stem cells (ESC) and 2. Non-embryonic stem cells. From (Figure. 12) 
embryonic stem cells have the property of being pluripotent or totipotent due to their 
nature to differentiate into new cell type. Non-embryonic stem cells (non-ESC) are 
multi-potent as these cells have a more limited potential to differentiate into various 
cell types. 
Introduction 
23 
 
 ESC have a great ability to spontaneously differentiate and are more prevalent as 
non-ESC (Thomson et al. 1995); (Thomson und Marshall 1998); (Tuch 2006). ESC 
cells are obtained from the inner cell mass of blastocysts, which is formed in the 
initial days of pregnancy, when the blastocyst implants the uterus. These stem cells 
derived from human blastocyst have normal karyotype, express cell surface markers 
and have high telomerase activity. Under favorable microenvironment these cells 
contribute to the formation of three germ layers, namely endoderm, mesoderm and 
ectoderm. There are two distinct subtypes of blastocyst derived stem cells: 1. ESC 
and 2. Trophoblast stem cell (TSC). TSC help to study  trophoblastic development, 
which could provide important information for managing pregnancy related 
pathologies in human (Tanaka et al. 2014). 
 
 
 
Figure 12. Schematic representation of blastocyst derived stem cells 
Modified (Landry und Zucker 2004)                               
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1.14 Cancer stem cell (CSC) 
ESC and TSC can be characterized by the presence of transcription factors 
responsible for the stemness and by cell surface proteins which support maintaining 
stem cell properties.  It has been reported (Figure. 13) that TSC have the ability to 
differentiate into embryonic lineages which may enact as tumor cells. (Lansdown und 
Rees 2011); (Shih Ie 2011); (Sivasubramaiyan et al. 2009).  Cancer stem cells (CSC) 
were first reported in acute myeloid leukemia (AML) expressing CD34 (Lapidot et al. 
1994). They a rare population of cells which has indefinite potential for self-renewal 
driving tumorigenesis (Reya et al. 2001).  
 
 
Figure 13. Schematic representation of the cell heterogeneity in stem cells 
Normal cancer cells and cancer stem cell population, modified (Reya et al. 2001) 
During blastocyst implantation and invasion, trophoblast cells differentiate in a 
fashion mimicking cancerous cells and during cancer progression there is similar 
behavior of cell differentiation and proliferation as during blastocyst implantation and 
invasion. CSC is involved as a subpopulation of tumor cell. CSC and TSC are used in 
research aiming to treat pathologies and diseases which might give valuable 
information to find novel treatments.  
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SOX2, Oct-4, NANOG and CDX2 are transcriptional factors essential to maintain 
self-renewal and undifferentiated stem cells. The expression of surface molecules 
characterizes stem cells, such as CD44 (multi structural and multifunctional cell 
surface molecule which is involved in cell differentiation, cell migration, cell 
proliferation), CD24 (cell adhesion molecule), CD34 (cell adhesion factor and cell 
migration) and CD133 (involved in stem cell differentiation and cell invasion). 
1.15 3D culture-Spheroid 
The 3-dimentional (3D) cell culture system is an artificial environment where 
biological cells are allowed to grow and interact with their surrounding 3-
dimensionally. Living tissue cells exist in 3D microenvironment with cell-cell and cell-
matrix communication and complex transport machinery for nutrients for the growth 
of cells. When cells are grown on non-adherent surfaces they may form spheroid 
structures that mimic the 3D environment. 3D culture systems reflect the complexities 
of tissues more realistic than conventional 2D systems (Friedrich et al. 2009). 
1.16 PIM kinases -LIF-Stem cell-trophoblast  
As it is stated previously PIM kinases are mainly regulated by the cytokine dependent 
JAK/STAT pathway.  LIF is one of the important factors playing a crucial role during 
implantation, placentation, trophoblast formation and invasion, migration and 
proliferation and signals via the JAK/STAT pathway. Pluripotency is supported by 
PIM kinases (PIM and PIM3) (Aksoy et al. 2007); (Iwakura et al. 2011). PIM3 kinase 
regulates STAT3 signaling which inhibits cell proliferating in human liver cancers 
(Wang et al. 2014). PIM kinases are found to support the propagation of 
mesenchymal  stem cells (Zhao et al. 2014) and PIM1 kinase in rejuvenation of 
human cardiac progenitor cells (Mohsin et al. 2013).  
Hence these above mentioned data triggered and lead to the aim of this study. 
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CHAPTER 2 OBJECTIVE 
To characterize PIM kinase functions and the stem cell like properties of trophoblastic 
cells. 
2.1 Part I 
To identify PIM kinases in trophoblastic cells. 
To analyze the effect of LIF stimulation on trophoblastic cells.  
To investigate the functional effects of a chemical inhibitor for PIM kinase. 
 
2.2 Part II 
To characterize the spheroids formation of HTR8/SVneo cell that resembles their 
Cancer stem cell (CSC) like properties. 
To analyze the effect of cytokines stimulation on the formed spheroids. 
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2.3 Experimental Design Part I 
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2.4 Experimental Design Part II 
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CHAPTER 3 MATERIALS AND METHODS 
3.1. Part I 
3.1.1 General Procedure 
All investigations were carried out by applying different methods and were performed 
at least three times. Information regarding each method has been described below, 
followed by materials and further specific information on individual methods. 
3.1.2 Reagents and antibodies or compounds 
Antibodies against PIM1, PIM2 and PIM3 kinase, BCL-XL, phospho-BAD, BAD, 
CASP3, cleaved CASP3, cleaved PARP, phospho-c-MYC, c-MYC, GAPDH, alpha 
tubulin, and HRP secondary antibody, were purchased from Cell Signaling 
Technologies (UK). Recombinant Human Leukemia Inhibitory Factor (LIF) was 
purchased from Merck Millipore (Germany). SGI-1776 a chemical inhibitor for PIM 
kinases was purchased from Merck Millipore (Germany). 
3.1.3 Ethical aspects 
Experimental investigation of placentae was performed based on a vote of the local 
ethics committee at the Friedrich-Schiller University Jena. All analyzed placentae 
were destined for disposal. 
 
Table 3. Culture conditions and Cell line conservation  
Cell line Culture 
properties 
Organism Morphology Biosafety 
level 
Origin Tissue 
Primary 
trophoblast 
cells 
Adherent Human Epithelial 2 First or third 
trimester  
Placenta 
HTR8/SVneo 
(GrahamCH,’93) 
Adherent Human Fibroblast 1 Immortalized 
primary 
trophoblast cell 
Placenta 
JEG-3 
(Kohler’70) 
Adherent Human Epithelial 1 Choriocarcinoma Placenta 
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The immortalized human primary trophoblast cell line HTR8/SVneo was a kind gift from Dr. 
Charles Graham, Ontario, Canada, the choriocarcinoma cell line JEG-3 was obtained from 
ATCC® HTB-36™. Both cell lines were maintained in the recommended tissue culture 
media supplemented with 10% fetal bovine serum (FBS) (Sigma Aldrich, Steinheim, 
Germany), 1000 U/ml penicillin and streptomycin (Life technologies, Grand Island, New 
York, USA). Cell lines were verified as authentic and were tested for mycoplasma 
contamination on a quarterly basis using mycoplasma kits (INtRON biotechnology Inc. 
Sungnam, Korea), which were found to be negative. All cells were grown under 
standardized conditions (37°C, 5% CO2, humidified tissue culture incubator). HTR8/SVneo 
(monolayer) were cultured in RPMI medium (Life technologies) and JEG-3 (monolayer) 
was cultured in Hams F12 media (Life technologies). 
3.1.4 Isolation of primary trophoblast cells 
The primary trophoblast cells were isolated from term placenta tissue not more than 1 h 
following collection. The protocol for isolation was adapted and modified from  (Kliman et 
al. 1986) and (Moore et al. 1997) in our Placenta Laboratory. In brief, placenta tissue was 
cut into small pieces followed by a washing step in sterile 1X PBS to remove blood as 
much as possible. Tissue was transferred into a new tissue culture flask. The obtained 
tissue samples were digested enzymatically with a mixture of collagenase, proteases and 
DNase for 30 min at 37° C. After a washing step the isolated cells were separated by a 
Percoll gradient (Percoll, Pharmacia, Sweden) and centrifuged at 100 g for 10 min. The 
layer within the 25% Percoll was carefully collected and washed. To avoid contamination 
RNA lysis buffer was added to the collected isolated cells.  
3.1.5 RNA extraction, PCR and quantitative real-time PCR 
Total cellular RNA was extracted using TRIZOL reagent (Invitrogen, Darmstadt, Germany) 
and quantification of total RNA was determined by Nano Drop ND-1000 
spectrophotometer (PeqLab Biotechnologies GmbH, Erlangen, Germany). Samples with 
purity ratio more than 1.8 at A260/A280 were stored at -80°C. cDNA was generated from 
150 ng-300 ng of DNase-free RNA using Maxima Reverse Transcriptase (Thermo Fisher 
Scientific Biosciences GmbH, Waltham, MA, USA) as per manufactures’ instructions. 
Reverse transcription (RT) was performed using a thermocycler (Eppendorf, Germany).  
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Amplification reactions were set up in a reaction volume of 20µL by use of Dream Taq 
DNA Polymerase (Thermo Fisher Scientific Biosciences GmbH, Waltham, MA, USA) and 
real time quantitative polymerase chain reaction was performed using SYBR green master 
mix with ROX reference dye (Thermo Fisher Scientific Biosciences GmbH, Waltham, MA, 
USA) in a Real-time PCR machine Stratagene Mx3005P (Agilent Technologies Inc., Santa 
clara, CA, USA). PCR primers were self-designed using software tools NCBI, genome 
browser, Primer3 and the specificity were confirmed using Keinefold and InsilicoPCR 
UCSC genome browser respectively. The applied concentrations ranged from 0.1 μM up 
to 1 μM, followed by a gradient PCR and real time PCR. Briefly, HTR8/SVneo and JEG-3 
were cultured and seeded in 6 well plates at a density of 4.5x105 cells/well, followed by 
incubation until 24 h to reach 80% confluence and cells were stimulated with LIF 
(10ng/mL). Highly purified salt-free primers for the target genes PIM1 PIM2 and PIM3 
(Sigma Aldrich Germany) have been designed and optimized to an equal annealing 
temperature of 60°C. PCRs were optimized in a Thermo cycler (Master cycler Gradient, 
Eppendrorf, Germany) with regard to Dream Taq. 
 
Table 4. Primer Details 
 
 
 
 
 
 
 
 
 
Gene Name 
(PCR Product) 
Primer sequence Gene ID 
 
PIM1(109bp) 
Fwd 5’CATCCTTATCGACCTCAATCG-3’  
NM_001243186.
1 
Rev 5’TATACACTCGGGTCCCATCG-3’ 
 
PIM2 (107bp) 
Fwd 5’TCACAGATCGACTCCAGGTG-3’  
NM_006875.3 
Rev 5’CATAGCAGTGCGACTTCGAG-3’ 
 
PIM3 (128bp) 
Fwd 5’ATGCTGCTCTCCAAGTTCGGCTCCCTGGCG-3’  
NM_001001852.
3 
 
Rev 5’ TCCTGTGCCGGCTCGGGTCGCTCCAGCACC 3’ 
 
HMBS (281bp) 
Fwd 5’ GAAATCATTGCTATGTCCACCAC 3’  
NM_008093.1 
Rev 5’ CTTCCCACCACACTCTTCTC 3’ 
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Table 5. Conventional PCR program 
 
 
 
 
 
 
 
 
Table 6. Real-time PCR program 
 
 
 
 
 
 
 
 
 
Step 
 
Temperature °C. 
 
Time 
 
Number of Cycles 
Initial denaturation 95 1 min 1 
Denaturation 95 30 s 
 
40 
Annealing Tm-5 30 s 
Extension 72 1 min 
Final Extension 72 10 min 1 
 
Step 
 
Temperature °C. 
 
Time 
 
Number of Cycles 
Initial denaturation 95 10 min 1 
Denaturation 95 15 s 
 
40 
Annealing 60 30 s 
Extension 72 30 s 
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3.1.6 Gel Electrophoresis 
Gel electrophoresis was performed to separate the PCR amplificates. According to the 
fragment size 2% agarose gel electrophoreses were prepared with additional 4 µl –
“20,000X Red Safe Nucleic Acid staining solution” (final concentration 1X) (INtRON 
biotechnology Inc. Sungnam, Korea). All PCR amplificates were mixed with 6X orange 
DNA loading dye (Thermo Fisher scientific, Bioscience, USA) final concentration 1X and 
filled into the well pockets of the prepared gels. Detection for the fragment length was 
performed by adding 5 µl of the O’GeneRuler 50bp DNA ladder (Thermo Fisher scientific, 
Bioscience, USA) and loading on the gel.  
Amplificates and ladder were separated with electric field of constant voltage 90 V in an 
electrophoresis chamber (PeqLab Biotechnologies GmbH, Erlangen, Germany) filled with 
1X Tris-acetate-EDTA buffer (TAE). All separated DNA fragments were visualized using 
Ultra violet (UV) light based detection system MF-ChemiBIS 3.2” (Biostep, DNR Bio-
Imaging systems, Jerusalem, Israel) and the corresponding "Gel capture" software 
(Version 5.1). 
3.1.7 Western blotting 
The expression of PIM kinases (PIM1, PIM2 and PIM3) was analyzed by Western blot.  
Briefly, cells were seeded in 6 well plates at a density of 4.5x105 cells/well, and each plate 
was incubated for 24 h to reach adherence and confluence. Subsequently, after serum 
starvation for 4 h, cells were stimulated with or without LIF (10 ng/ml) from 2 minutes until 
60 minutes. Then, cells were rinsed with cold phosphatase buffered saline (PBS; 1X; GE 
healthcare or PAA, Pasching/Linz, Austria) and harvested. The cells were lysed using Cell 
lysis buffer (Cell Signaling Technologies Inc., Beverly, Massachusetts) and lysates were 
centrifuged at 10,000 x g for 10 min at 4° C. Protein concentrations of the resulting 
supernatant were determined at 660 nm using a Pierce® BCA Protein Assay (Thermo 
Fisher Scientific Biosciences GmbH, Waltham, MA, USA).  Total protein (20-30µg) 
equivalent concentrations of cell lysate protein were boiled for 7 min at 95° C and resolved 
in 10-12% SDS PAGE electrophoresis at 60 mA constant for 1 h, followed by protein 
transfer to a PVDF membrane (Thermo Fisher Scientific Biosciences GmbH, Waltham, 
MA, USA).  
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Membranes were blocked with 5 % bovine serum albumin (BSA) in Tris-buffered saline 
containing 0.1 % Tween 20 (TBST) for 1 h before overnight incubation at 4° C with various 
primary antibodies: anti-PIM1, anti-PIM2, anti-PIM3, anti-BCLXL, anti-phospho-BAD, anti-
BAD, anti-c-MYC, anti-phospho-c-MYC, anti-CASP 3, anti-cleaved CASP 3 and anti-
cleaved PARP, typically at 1:1000 dilution. Blots were rinsed with 1X TBST and incubated 
with a secondary antibody anti-rabbit IgG, HRP-linked (Cell Signaling Technologies, 
Beverly, Massachusetts) at a dilution 1:10,000 for 90 min at room temperature. Reactive 
bands were visualized by exposure to Luminata Forte Western HRP substrate (Merck 
Millipore, Billerica, Massachusetts) a chemical reagent for detection.  
Expression was quantified by using the ultra-sensitive chemiluminescence gel 
documentation system MF-ChemiBIS 3.2” (Biostep, DNR Bio-Imaging systems, 
Jerusalem, Israel) and densitometry quantification of the respective band intensities was 
performed using Gel capture Total Lab 1000 image program software. 
3.1.8 Immunocytochemistry (ICC) 
Immunocytochemistry was performed to confirm the localization and distribution of the 
expression of PIM kinases in the cell models. HTR8/SVneo and JEG-3 cells were cultured 
on super frost plus microscope slides (Thermo Scientific, USA) in slides culture chambers 
(NUNC quadri PERM, Germany). Before seeding the cells , cell culture slides were 
washed in ethanol (75%) and placed into  slide chamber until air dry. 100,000 cells/slides 
were seeded and incubated overnight followed by LIF (10 ng/ml) stimulation up to 1 h. 
Staining of cells was performed by using Vectastain Elite rabbit IgG kit (Vector 
Laboratories, Burlingame, USA). Cells were fixed with methanol/ethanol (1:1) for 5 min 
followed by washing steps with 1X PBS and permeabilized and blocked using 10% goat 
serum in 0.1% Tween 20 in PBS for 20 min. Cells were washed 3 times in PBS (1X) (GE 
healthcare or PAA, Pasching/Linz, Austria) and incubated with 1:100 diluted primary 
antibodies anti-PIM1, anti-PIM2, anti-PIM3 (Cell Signaling) or rabbit (DA1E) mAb IgG 
Isotype control (Cell Signaling) in antibody diluent (DAKO, Hamburg, Germany) for 1 h. 
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Later, the slides with cells were rinsed 3 times with PBS (1X) and incubated with 
biotinylated affinity-purified anti-rabbit-IgG (Cell Signaling Technologies) for 30 min, 
followed by treatment with a solution of avidin/Biotinylated enzyme complex (ABC; Thermo 
Fisher Scientific, Bonn, Germany), followed by 2 min substrate staining with DAB 
chromogen (DAKO, Hamburg, Germany), followed by washing in distilled water for 2 min 
and finally, by counterstaining with haematoxylin solution for 1 min. The so prepared slides 
were dehydrated by ethanol-to-xylene treatment and embedded with Histofluid (Paul 
Marienfild, Lauda-Köngshofen, Germany). The images of the slides were visualized on a 
Zeiss Axioplan2 microscope (Carl Zeiss, Jena, Germany). 
3.1.9 Immunofluorescence (IF) 
HTR8/SVneo and JEG-3 cells were cultured on super frost plus microscope slides 
(Thermo scientific, USA). Cell culture slides were washed in ethanol (75%) and placed into 
a  slide chamber until air dry. 100,000 cells/slides were incubated overnight followed by 
LIF (10ng/ml) stimulation up to 1 h. Staining of cells was performed by using Vectastain 
Elite rabbit IgG kit ( vector Laboratories, Burlingame, USA) where cells were fixed with 
methanol/ethanol (1:1) for 5 min followed by washing steps with 1X PBS and 
permeabilization and blocking by using 10% goat serum in 0.1% Tween 20 in PBS for 20 
min. Cells were washed 3 times in PBS (1X) (GE healthcare or PAA, Pasching/Linz, 
Austria) and incubated with the primary antibodies (1:200 dilution) anti-PIM1, anti-PIM2, 
anti-PIM3 (Cell signaling) or rabbit (DA1E) mAb IgG Isotype control (Cell Signaling 
Technologies) in antibody diluent (DAKO, Hamburg, Germany) overnight at 4 °C. Later, 
cells were rinsed 3 times with PBS (1X) and incubated with secondary antibody labeled 
with fluorescent Cy3 conjugated goat anti-rabbit-IgG (Dianova GmbH, Hamburg, 
Germany) for 1 h at room temperature, followed by the treatment of the solution with 
avidin/biotinylated enzyme complex (ABC; Thermo Fisher Scientific, Bonn, Germany), by 
DAPI (4', 6-diamidino-2-phenylindole) mounting media staining and embedding. The 
images of the slides were visualized on a Zeiss Axioplan2 microscope (Carl Zeiss, Jena, 
Germany). 
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3.1.10 Incubation of cells with PIM-Kinase Inhibitor IX, SGI-1776 
SGI-1776 {N-((1-Methylpiperidin-4-yl)methyl)-3-(3(trifluoromethoxy)phenyl)imidazo[1,2-
b]pyridazin-6-amine, 2H₂SO₄AS (Calbiochem ®, Millipore Merck, Darmstadt, Germany) is 
a chemical inhibitor for PIM kinases which  is ATP competitive inhibitor of PIM1,2,3 and 
had to be resolved in dimethlysulfoxide (DMSO) (Sigma Aldrich, Steinheim, Germany). 
The respective DMSO concentration in medium served as negative control. 500.000 
cells/well were seeded in 6 well plates.  
After 24 h, cells were treated with either PIM1 kinase inhibitor SGI-1776 or DMSO (0.01%) 
control vehicle reagents. After incubation for further 24 h protein was extracted for Western 
blotting. 
3.1.11 Cell Viability Assay (MTS)  
Viable cells were evaluated using a colorimetric MTS (3-(4, 5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) CellTiter 96® AQueous One 
Solution Cell Proliferation Assay (MTS) (Promega, USA). Cells were seeded at a density 
of 5 x 103 cells/well in triplicates in 96-well plates with outer wells left for blank. After 24 h 
of incubation, the media was changed and 0.01% DMSO vehicle, or SGI-1776 at different 
concentrations (5 µM, 10 µM and 20 µM) were added and incubated. After further 24 h, 0.5 
mg/ml MTS dye was added and the cells were incubated for an additional 4 h prior to 
measurement. Formazan crystals were dissolved in DMSO for 5 min and the plates were 
read at 490 nm wavelength spectrophotometrically with a reference of 650nm.  
3.1.12 Cell Proliferation (BrdU) 
Cell proliferation was quantified using 5’-bromo-2’-deoxyuridine (BrdU) incorporation, a 
Cell Proliferation ELISA, BrdU (Colometric) kit (Roche Diagnostics GmbH, Mannheim, 
Germany).  It is based on the detection of BrdU incorporated into genomic DNA of 
proliferating cells. Cells were seeded at a density of 5 x 103 cells/well (in a final volume of 
100 µl/well) in triplicates in 96-well plates with outer wells left for distilled water. After 24 h 
of incubation, the media was changed followed by incubating the cells with or without SGI-
1776 at different concentrations (5 µM, 10 µM and 20 µM) or 0.01% DMSO vehicle for 24 
h at 37 °C at 5% CO2. Briefly, cells were labeled with BrdU and allowed to accrue within 
proliferation cells for 2 h.  
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Next step, cells were fixed by using FixDenate for 30 min at room temperature followed by 
incubating with an anti-BrdU-POD monoclonal antibody for 90 min.  
Later, the antibody conjugate was removed by flicking off and washing the wells three 
times with washing solution PBS 1X.  Finally, substrate solution was added and incubated 
until color development was sufficient. Absorbance was measured at 492 nm. 
 
3.1.13 Apoptosis (Annexin V assay) 
Apoptosis was measured by flow cytometry using an annexin V FITC conjugated (Immuno 
Tools, Freisoythe, Germany) and Propidium Iodide (PI) apoptosis kit (BD Bioscience USA) 
according to manufacturers’ instructions. Briefly, cells were seeded in 6 well plates at a 
density of 4.5x105 cells/well, and incubated for 24 h to reach adherence and confluence, 
followed by incubation with or without SGI-1776 at different concentrations (5 µM, 10 µM 
and 20 µM) or and 0.01% DMSO vehicle. After further incubation for 24 h at 37 ° C at 5% 
CO2, cells were harvested, washed with cold PBS (1X) and re-suspended in annexin V 
FITC conjugated (which binds extra-cellularity to apoptotic cells)/ Propidium iodide (PI; 
which stains necrotic cells) for 15mins in dark at room temperature. Fluorescence of 104 
labeled cells was measured by flow cytometry using a FACSCalibur ™ (BD Bioscience 
USA). Viable cells were quantified by subtracting the apoptotic (Annexin V-FITC positive) 
and necrotic fractions (PI positive).  
3.2 PART II 
3.2.1 Cell cultures and cell line 
The immortalized human primary trophoblast cell line HTR8/SVneo was used for 
experiments. The cell line was maintained under standardized conditions (37°C, 5% CO2, 
humidified atmosphere). HTR8/SVneo cells were cultured in RPMI medium supplemented 
with 10% fetal bovine serum (FBS) and 1000 U/ml Penicillin and streptomycin. 
3.2.2 Generation of spheroids 
Cells were cultured and seeded on non-adherent petri dishes (Greiner, Germany) at a 
density of 1X106 cells/petri dish, incubated for 72 h (humidified atmosphere, at 37 °C and 
5% CO2). Subsequently, spheroids were formed. 
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3.2.3 Viability analysis of formed spheroids  
The spheroid viability was analyzed by application of cell tracker dyes, which stain living 
cells (Cell Tracker™ Probes for long-term tracing of living cells: Cell Tracker™ Green 
BODIPY; 8-chloromethyl-4, 4-difluoro-1, 3, 5, 7-tetramethyl-4-bora-3a, 4a-diaza-s-
indacene; Life Technologies, Germany). Spheroids formed on 5th to 7th day were taken for 
analysis after centrifugation and aspiration of the supernatant. The spheroids were gently 
re-suspended in pre-warmed Cell Tracker™ dye working solution and incubated for 15–45 
min. Subsequently, cells were centrifuged at 1300 rpm for 5 min. The dye working solution 
was replaced with fresh, pre-warmed medium and cells were incubated for another 30 
minutes at 37°C and 5% CO2 and observed under microscope. 
3.2.4 Spheroid Stimulation 
Spheroids were formed under simultaneous stimulation with 10 and 50 ng/ml human 
recombinant LIF (Millipore Merck, Germany) or human recombinant OSM (Life 
Technologies, Germany) or without as control. 
3.2.5 Flow Cytometry 
The HTR8/SVneo cells cultured as monolayers or spheroids were stimulated with LIF or 
OSM (10 ng/ml and 50 ng/ml). After 72 h, the monolayer cells and spheroids were stained 
with fluorescence labeled antibodies against surface molecules CD44 (multi structural and 
multifunctional molecule involved in cell differentiation, migration, and proliferation), CD34 
(adhesion molecule, migration and invasion), CD24 (cell adhesion molecule) and CD133 
(involved in stem cell differentiation and cell invasion) (all from Miltenyi Biotech GmbH 
Bergisch Gladbach, Germany) and incubated at 4 °C  in a shaker Orbital Taumler Plymax 
1040 (Heidolph Instruments GmbH & Co. KG, Schwabach, Germany). After 30 min, cells 
were washed in PBS 1X, resuspended in FACS Flow buffer ( BD, Bioscience, USA) and 
analyzed on a flow cytometry FACS Calibur ( BD, Bioscience, USA). 
3.2.6 Western Blot 
The expression of CDX2, SOX2, OCT4 and NANOG, which are transcriptional factors 
essential to maintain self-renewal and the status of undifferentiated embryonic stem cells, 
was analyzed by Western blotting. 
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The formed spheroids were harvested and rinsed with cold PBS (1X) (GE healthcare or 
PAA, Pasching/Linz, Austria) and harvested. Spheroids were lysed using Cell lysis buffer 
(Cell Signaling Technologies Inc., Beverly, Massachusetts) and cell lysates were 
centrifuged at 10,000 x g for 10 min at 4°C. Protein concentrations of the resulting 
supernatant were determined by a Pierce® BCA Protein Assay (Thermo Fisher Scientific 
Biosciences GmbH, Waltham, MA, USA) at 660 nm wavelength. Total protein (20-30 µg) 
equivalent concentrations of cell lysate protein were boiled for 7 min at 95° C and resolved 
in 10-12% SDS PAGE electrophoresis at 60 mA constant for 1 h, followed by protein 
transfer to PVDF membrane (Thermo Fisher Scientific Biosciences GmbH, Waltham, MA, 
USA). Membranes were blocked with 5 % bovine serum albumin (BSA) in Tris-buffered 
saline containing 0.1 % Tween 20 (TBST) for 1 h before overnight incubation at 4° C with 
primary antibodies against CDX2, NANOG, OCT4A, and SOX2, typically at 1:1000 
dilutions. Blots were rinsed with 1X TBST and incubated with a secondary HRP-linked 
anti-rabbit IgG antibody (Cell Signaling Technologies Inc., Beverly, Massachusetts) at a 
dilution 1:10,000 for 90 min at room temperature. Reactive bands were visualized by 
exposure to Luminata Forte Western HRP substrate (Merck Millipore, Billerica, 
Massachusetts) a chemical reagent for detection. Expression was quantified by using the 
ultra-sensitive chemiluminescence gel documentation system MF ChemiBIS 3.2 (Biostep 
DNR Bio-Imaging systems, Jerusalem, Israel) and densitometry quantification of the 
respective band intensities was performed using Total Lab 1000 image program software.  
3.3 Statistics 
All experiments were repeated at least three times. Data is presented as mean ± Standard 
Deviation (SD). The quantification was done using delta delta cycle threshold (∆∆Ct) 
method. Two-tailed Student’s t-test was performed for statistical comparisons between 
experimental groups. P<0.05 was defined as statistically significant. 
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CHAPTER 4 RESULTS 
PART I 
4.1 Identification of PIM kinases (PIM1, PIM2 and PIM3) in trophoblastic 
cells 
All three PIM kinase family members were expressed at the mRNA level in primary 
trophoblast cells, HTR8/SVneo (immortalized transformed trophoblast cells) and JEG-3 
(choriocarcinoma) cells (Fig 14.). Shown is the PCR agarose gel electrophoresis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. PCR gel electrophoresis PIM kinase expression 
(A) expression PIM kinase in primary trophoblast cells (T1-T3), HTR8/SVneo, JEG-3 and K562 
(Leukemic) cells.(B) PIM3 kinase re-designed primer. 
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4.2 Effect of LIF upon stimulation in trophoblastic cells  
During pregnancy LIF plays a very important role in trophoblast functions, hence we have 
stimulated the cell lines (HTR8/SVneo and JEG-3) with LIF (10 ng/ml) from 2’-60’ min and 
studied the expression level of PIM kinase family members (PIM1, PIM2 and PIM3), by 
real-time quantitative polymerase chain reaction (qPCR) and Western blot analysis. (n=3). 
 
4.2.1 Gene expression level 
In HTR8/SVneo cells, the gene expression level of PIM1 and PIM3 kinase was significantly 
increased 60 min after LIF stimulation whereas PIM2 kinase was not significantly altered 
(Fig 15.A). In JEG-3 cells the gene expression levels of PIM2 (2 min after LIF stimulation) 
and PIM3 kinase (60 min after LIF stimulation) exhibits significant increase but not that of 
PIM1 kinase (Fig 15.B). The fold changed was observed by normalization to reference 
gene HMBS. K562 was not positive for all PIM kinase so it was not further used in this 
study. 
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Figure 15. Fold change in the expression of PIM Kinases 
PIM1, PIM2, and PIM3 in HTR8/SVneo (A) and JEG-3 cells (B). Cells were stimulated with LIF (10ng/ml) (n=3- 
independent experiments, Mean ± SD * P< 0.05). 
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4.2.2 Protein expression level 
The protein synthesis of PIM kinases family members upon LIF simulation was analyzed 
by Western blotting. As above the cells were stimulated, followed by protein isolation, 
quantification and separation of proteins in SDS-PAGE gel. The proteins were transferred 
onto membranes, incubated with specific antibodies and the respective bands were 
visualized by cheminoluminescence. Immunoblots of HTR8/SVneo (Fig.16.A) and JEG-3 
(Fig.17.A) are shown below. After LIF stimulation, in HTR8/SVneo cells the relative 
expression of PIM1 (Fig.16. B) and PIM3 (Fig.16. D) Kinases were significantly increased. 
However, PIM2 kinase showed an increase during the first 20 min followed by a decrease 
(Fig.16.C). In JEG-3 cells, the relative expression level of PIM2 (Fig.17. C) and PIM3 
(Fig.17.D) kinase were significantly increased, but PIM1 kinase was decreased upon LIF 
stimulation (Fig.17.B). The relative expression was quantified by densitometry and 
normalized to reference protein alpha-tubulin in all protein analysis experiments.  
 
 
 
  
  
 
 
 
 
 
 
 
Results 
 
44 
 
 PIM2
0
0.5
1
1.5
2
2.5
3
0 2 10 20 30 60 min
Time period LIF stimulation
R
e
la
ti
v
e
 e
x
p
re
s
s
io
n
 l
e
v
e
l **
**
C
 
 
 
 
 
 
 
 
PIM3
0
0.5
1
1.5
2
2.5
3
0 2 10 20 30 60 min
Time period LIF stimulation
R
e
la
ti
v
e
 e
x
p
re
s
s
io
n
 l
e
v
e
l
***
***
****
D
 
Figure 16. Protein expression in HTR8/SVneo cells. 
(A) Representative Immunoblots of the protein expression of PIM1, PIM2, and PIM3 upon LIF 
stimulation in HTR8/SVneo cells. (B, C and D) Densitometry analysis of the relative expression of 
PIM1, PIM2, and PIM3 kinases in HTR8/SVneo cells. PIM1 and PIM3 kinase expression in 
HTR8/SVneo cells shows an increase, whereas PIM2 was increased for short duration, later 
decresed (* p< 0.05; p< 0.01; p< 0.001 Student’s t-test). Cells were stimulated with LIF (10 ng/ml). 
Normalized to loading control alpha-tubulin. n=3- independent experiments, Mean ± SD 
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Figure 17. Protein expression in JEG-3 cells. 
(A)  Representative Immunoblots of the protein expression of PIM1, PIM2, and PIM3 with tubulin 
as reference control upon LIF stimulation in JEG-3 cells. (B, C and D) Densitometry analysis of the 
relative expression of PIM1, PIM2, and PIM3 in JEG-3 cells. PIM2 and PIM3 kinase expression in 
JEG-3 cells shows an increase, whereas PIM1 was relatively decreased (*p< 0.05; p< 0.01; p< 
0.001; Student’s t-test).  Cells were stimulated with LIF (10ng/ml). Normalized to loading control 
alpha-tubulin. N=3- independent experiments, Mean ± SD. 
 
4.2.3 Localization and distribution of PIM kinases 
Immunostaining was performed to investigate the morphological localization and 
distribution of PIM kinases in cell lines. Both immunocytochemistry (ICC) and 
immunofluorescence (IF) staining were used to study the expression of PIM1, PIM2 and 
PIM3 kinases upon LIF stimulation up to 1 h. Below figures represent the morphological 
distributions of PIM1 kinase. In unstimulated cells, PIM1 kinase was localized in 
cytoplasmic, PIM2 in the nucleus and PIM3 was present all over the cells. Upon LIF 
stimulation, in HTR8/SVneo (Fig. 18) PIM1 and PIM2 kinase has evidently increase  
whereas PIM3 kinase is decreased distribution with respect to Isotype control and 
unstimulated. In JEG-3, (Fig. 19) PIM1 and PIM3 (evidently increased) whereas PIM2 
kinase is not evidently increase after LIF stimulation. 
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Figure 18. Immune staining in HTR8/SVneo cells. 
IF (From left three columns, merge; nuclei:  DAPI; blue, Cy3: red) and ICC (right column, DAB 
staining -brown) staining showing expression of PIM1, PIM2 and PIM3 kinases in HTR8/SVneo 
cells. PIM1 and PIM2 show an increase, PIM3 show decrease upon stimulation with LIF (10 ng/ml, 
1 h). 
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Figure 19. Immune staining in JEG-3 cells 
IF (From left three columns, merge; nuclei:  DAPI; blue, Cy3: red) and ICC (right column, DAB 
staining -brown) staining showing expression of PIM1, PIM2 and PIM3 in JEG-3 cells.PIM1, PIM2 
and PIM3 shows an increase compared upon stimulation with LIF (10 ng/ml, 1 h). 
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4.3 PIM kinase inhibition in trophoblastic cells by SGI-1776 
Cells were incubated with chemical inhibitor, PIM-Kinase Inhibitor IX, SGI-1776; used to 
inhibit the PIM kinases activity. The functional investigation shows the effect of SGI-1776 
on cell viability and proliferation. (n=3) 
 
4.3.1 Effect on Cell viability and proliferation  
The viability of cells upon SGI-1776 inhibition decreased in dose dependent manner with 
respect to controls. On day 1 and 2, there was significant reduction of viability at 10 and 20 
µM SGI-1776. On day 3 at 20µM there were no viable cells in neither cell line. In 
HTR8/SVneo cells (Fig. 20 A) there was significant decrease in proliferation on day 1 at 20 
µM SGI-1776, on day 2 and day 3 at 10 and 20µM. In JEG-3 cells (Fig. 20 B) on day 1 at 
concentrations of 10 and 20µM SGI-1776 decreased viability on day 1 and which was 
almost completely inhibited on days 2 and day 3. Hence the above data demonstrate that 
PIM kinases inhibition reduces the cell viability. 
The incorporation of BrdU showed similar effect as that of viability where, in HTR8/SVneo 
cells (Fig. 21 A) on day 1 there is reduction in proliferation rate of cells. On days 2 and 3 
showed significant decreased cell proliferation in dose dependent manner. In JEG-3 cells 
(Fig. 21 A) on day 1, day 2 and day 3 has decreased cell proliferation at 10 and 20 µM/ml 
concentrations respectively. 
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Figure 20. Cell Viability assay 
Effect of  PIM-kinase inhibitor IX, SGI-1776 (chemical inhibitor) on cell viability (MTS assay) in 
HTR8/SVneo (A) and JEG-3 cells (B), that were untreated, treated with 0.1% DMSO vehicle alone, 
or with 5 µM, 10 µM, or 20 µM for 24 h, 48 h or 72 h (n=3 independent experiments, mean ± SD;  
*p< 0.05, Student’s t-test). 
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Figure 21. Cell Proliferation assay 
Effect of  PIM-kinase inhibitor IX, SGI-1776 (chemical inhibitor) on cell proliferation (BrdU) in 
HTR8/SVneo (A) and JEG-3 cells (B), that were untreated, treated with 0.1% DMSO vehicle alone, 
or with 5 µM, 10 µM, or 20 µM for 24 h, 48 h or 72 h (n=3 independent experiments, mean ± SD;  
*p< 0.05, Student’s t-test).  
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4.3.2 SGI-1776 effect on potential PIM Kinase targets 
To elucidate the action mechanisms of PIM Kinases, we evaluated the effect of the 
inhibitor SGI-1776 on PIM kinase functions. HTR8/SVneo and JEG-3 cells were treated 
with vehicle DMSO (0.01%) alone or different concentrations of SGI-1776. Cells were 
harvested after 24 h incubation and compared with untreated cells. The total and 
phosphorylated protein expression of the PIM kinase target BAD were analyzed by 
immunoblot analysis (Fig 22. A).  
The phosphorylation level of BAD (ser112) compared with total protein was measured (Fig 
22.B). In HTR8/SVneo and JEG-3 cells, total BAD protein was found to have no change 
whereas Phosphorylated BAD was decreased at SGI-1776 concentrations of 5 µM. in both 
cell lines. There was also no significant change in the expression of anti-apoptotic proteins 
BCL-XL (Fig 22.B). 
 Apoptosis induction was confirmed by immunoblots for PARP and CASP 3 (Fig 23.A). By 
densitometry analysis of the blots, a 20µM SGI-1776 induced a significant increase of 
cleaved PARP and cleaved CASP 3 expression with no significant change in total CASP-3 
expression in both cell lines (Fig.23.B). 
In addition to BAD, another target of PIM Kinases phosphorylation is MYC. 
Overexpression of PIM Kinases are frequently associated with elevated MYC levels. Since 
MYC has an important role in tumor biology, we evaluated the effect of SGI-1776 on its 
phosphorylation in HTR8/SVneo and JEG-3 cells, phosphorylation of MYC at ser62 and 
total MYC by immunoblotting (Fig. 24. A).The densitometry analysis showed a significant 
decrease in the relative expression in c-MYC and p-C-MYC expression after treatment 
with SGI-1776 in a dose dependent manner (Fig.24.B) 
. 
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Figure 22. Immunoblot analysis of pro-apoptosic protein. 
(A) Immunoblot analysis of potential target proteins in HTR8/SVneo and JEG-3 cells. Cells were 
treated with 0.1% DMSO alone or with 5, 10, or 20 µM/ml SGI-1776 for 24 h. (B) (C) and (D) 
Densitometry analysis of potential PIM kinase target proteins in HTR8/SVneo and JEG-3 cells. The 
protein levels of p-BAD (ser112), total BAD and BCL-XL were normalized to GAPDH as loading 
control (n=3 independent experiments, mean ± SD, * p<0.05, ** p<0.01 Student’s t-test).
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Figure 23. Immunoblot analysis of anti-apoptotic proteins. 
(A) Immunoblot analysis of apoptosis indicating proteins (cleaved PARP, CASP-3, cleaved CASP-
3) in HTR8/SVneo and JEG-3 cells. Cells were treated with 0.1% DMSO alone or with 5, 10, or 20 
µM/ml SGI-1776 for 24 h. (B) Densitometry analysis of potential target proteins in HTR8/SVneo 
and JEG-3 cells. The protein levels of CASP3, cleaved CASP3 and cleaved PARP were 
normalized to tubulin loading control (n=3 independent experiments, mean ± SD, * p<0.05, 
Student’s t-test). 
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Figure 24. Protein analysis of Potential targets of PIM kinases 
(A) Immunoblot analysis of potential PIM Kinase target protein c-MYC in HTR8/SVneo and 
JEG-3 cells. Cells were treated with 0.1% DMSO alone or with 5, 10, or 20 µM/ml SGI-1776 
for 24 h 10 (B) Densitometry analysis of p-c-MYC and c-MYC in HTR8/SVneo and JEG-3 
cells. (n=3 independent experiments, mean ± SD, * p<0.05, Student’s t-test). 
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4.3.3 Apoptosis induction by SGI-1776  
Both cell lines HTR8/SVneo and JEG-3 cells were treated with different 
concentrations of SGI-1776, and then stained with annexin V-FITC/PI and analyzed 
by flow cytometry to measure the apoptosis induction (Fig. 25 and Fig. 26.). 
HTR8/SVneo cells were incubated for 24 h with 5, 10 and 20 µM/ml SGI-1776, 
which resulted in a significant increase in apoptosis (Fig. 25.A). After treating JEG-3 
cells with 20 µM SGI-1776 for 24 h, a significant increase in the apoptosis of more 
than 20% was observed (Fig. 26.A). 
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Figure 25. Apoptosis assay by annexin V showing the cell death in HTR8/SVneo cells. 
(A) Flow cytometry for Apoptosis assay by annexin V showing the cell death in HTR8/SVneo 
cells treated with SGI-1776. Cells were either treated with 0.1%DMSO alone or treated with 
5, 10, 20 µM/ml SGI-1776 and cells were harvested after 24 h and stained with annexin V 
and Propidium Iodide (PI). Lower panel represents the relative percentage of Apoptosis in 
HTR8/SVneo cells respectively. (n=3- independent experiments, Mean ± SD * P< 0.05). 
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Figure 26. Apoptosis assay by annexin V showing the cell death in JEG-3 cells 
(A) Flow cytometry for Apoptosis assay by annexin V showing the cell death in JEG-3 cells 
treated with SGI-1776. Cells were either treated with 0.1%DMSO alone or treated with 5, 10, 
20 µM/ml SGI-1776 and cells were harvested after 24 h and stained with annexin V and 
Propidium iodide (PI). Lower panel represent the relative percentage of apoptosis in JEG-3 
cells respectively. (n=3- independent experiments, Mean ± SD * P< 0.05). 
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PART II 
4.4 HTR8/SVneo cell characterization of Stem cell property  
4.4.1 Characterization of spheroids formed from HTR8/SVneo cells 
HTR8/SVneo cells were used as a model to investigate cancer stem cell like (CSC) 
properties exhibited upon 3-dimensional (3 D) culture by generating spheroids on a 
non-adherent surface.  
4.4.2 Morphology and cell viability by microscopic analysis 
Spheroid were generated seeding cells at a density of 1x106 cells on petri dishes 
(non-adherent) with or without stimulation with LIF (10 and 50 ng/ml) and incubated 
for up to 72 h under standard conditions. Formed spheroids were further analyzed 
and compared with cells cultured in conventional 2D models (Fig.27.A-C). Spheroids 
are small round-shaped aggregates of cells with diameters of approximately 50-
500µm. Spheroids were incubated with cell tracker fluorescence dye, which stains 
the viable cells (Fig.27.D-E) and Spheroids treated with LIF showed no change in 
morphology and number of spheroids generated (Fig. 27 F). 
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Figure 27. Spheroid formation in the HTR8/SVneo cell line 
(A) Initial monolayer morphology 200x; (B) 200X and (C) 400X: spontaneous spheroid 
formation on day 3 on non-adherent surface at 200µm and 400µm.(D) and (E) Viability test of 
spheroids via cell tracker staining at 200X and 400X respectively; (F) spheroids after LIF 
stimulation (no change in morphology, however tendency to form lower number of 
spheroids). 
4.4.3 Western Blot analysis  
Western blot analysis was performed with spheroids generated for stem cell 
transcription factors NANOG, CDX2, SOX2 and OCT4A. We detected, that spheroids 
formed from HTR8/SVneo cells express transcription factors involved in maintenance 
of stemness. These include CDX2 which is the most specific trophoblast stem cell 
marker and NANOG. Upon LIF stimulation, the expression of transcription factors 
was altered. NANOG expression increased and CDX2 expression (Fig. 28.A) 
decreased significantly in spheroids with 50 ng/ml LIF stimulation compared with 
control monolayer cultures. Vinculin served as housekeeping reference. SOX2 and 
OCT4A were not expressed, (data not shown). 
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Figure 28. Transcription factor for stem cell upon LIF stimulation. 
(A) Western blot detection of CDX2 and NANOG, (B) Densitometry analysis of stem cell-
related transcription factors in HTR8/Svneo monolayers and spheroids formed with/out LIF 
stimulation. Vinculin was used as reference protein, experiments accomplished in three 
independent experiments.  n=3 independent experiments, mean ± SD, * p<0.05, Student’s t-
test).  ML-Monolayer, S-Spheroid. 
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Upon OSM stimulation, the expression of transcription factors was altered. NANOG 
and CDX2 expression was increased (Fig. 28.A) significantly in spheroids with 50 
ng/ml OSM stimulation compared with control monolayer cultures. Alpha tubulin 
served as housekeeping reference. SOX2 and OCT4A were not expressed, (data not 
shown). 
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Figure 29. Transcription factor for stem cell upon OSM stimulation 
(A) Representative Western blots for detection of CDX2 and NANOG in HTR8/SVneo cells 
grown in monolayers or spheroids stimulated with different concentrations of OSM, (B) 
densitometry analysis of respective Western blots. Alpha tubulin was used as reference 
protein, experiments accomplished in three independent experiments.. Error bars indicate 
standard deviation. ML-Monolayer, S-Spheroid. 
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4.4.4 Flow cytometer analysis 
Flow cytometry analysis of HTR8/SVneo after LIF and OSM stimulation with different 
concentrations (10ng/ml and 50ng/ml) revealed alteration of surface molecules 
CD24, CD34 and CD44. In LIF treated spheroids cells there is significant decrease in 
the expression of CD24 at 10 ng/ml, upon LIF stimulation but rather the untreated 
spheroids showed significant increase in the expression of CD34 and CD44 showed 
interestingly low expression in spheroid but with no significant difference in LIF 
treatment (Fig 30. A). 
In OSM treated cells there was no significant difference observed in the surface 
molecules by flow cytometry analysis (Fig 31. A). 
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Figure 30. Flow cytometry analysis for stem cell property upon LIF stimulation. 
Upper panel (A) Histograms from flow cytometric analysis of stem cell surface marker 
expression on HTR8/SVneo spheroids formed with or without LIF stimulation for 72 h. M1 
indicates negative cells as defined by application of isotype control antibodies; M2 indicates 
positive cells.  Lower panel (B) Spheroids was generated from HTR8/SVneo cells stimulated 
with two different concentrations of LIF or without LIF. Expression of stemness-related 
surface markers was assessed by flow cytometry n=3 independent experiments, mean ± SD, 
* p<0.05, Student’s t-test).  ML-Monolayer, S-Spheroid.  
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Figure 31. Flow cytometry analysis for stem cell property upon OSM stimulation. 
Upper panel (A) Histograms from flow cytometric analysis of stemness-related cell surface 
marker expression on HTR8/SVneo monolayers (ML) and spheroids (S) formed with or 
without OSM stimulation for 72 h. M1 indicates negative cells as defined by application of 
isotype control antibodies; M2 indicates positive cells. Lower panel (B) Quantification of flow 
cytometry results. Expression of stemness-related surface molecules in monolayers was 
defined as 1 and that in spheroids was calculated, respectively (n=3; error bars indicate 
standard deviation). 
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CHAPTER 5 DISCUSSION 
PIM kinase where reported first in late 1980s in murine leukemia virus (MuLv) that 
was related to transcriptional activation of Pim-1 gene with enhanced expression  
(Cuypers et al. 1984)  (Selten et al. 1984). So far, its expression has been reported in 
almost all kind of human cancer (marking its presence to be important in cell survival, 
cell progression, cell migration, cell proliferation and apoptosis (Breuer et al. 1989). 
There is evidence that its overexpression leads to complications and is responsible 
for tumor progression. PIM kinases have three isoforms and all of them are very 
similar to each other which may lead to functional interference impairing growth and 
survival of cancer (Cuypers et al. 1984). Aberrant expression of PIM kinases is 
observed in pancreatic cancer and plays pivotal roles in the regulation of cell cycle, 
apoptosis, and properties of stem cells, metabolism, autophagy, drug resistance and 
targeted therapy. Blocking the activities of PIM kinases could prevent pancreatic 
cancer development (Xu et al. 2014b). PIM kinases are not only involved in cancer 
progression but it has been demonstrated that PIM kinases play an important role 
during embryonic development (Aksoy et al. 2007, Eichmann et al. 2000). These 
findings opened the path to study the role of PIM kinases during pregnancy, 
especially on trophoblast cell functions. The role of PIM kinase in trophoblast cells is 
unknown so far. The present study analyzes their expression and potential 
involvement in LIF-induced intracellular signaling. The current study demonstrates 
that LIF increases PIM kinase protein expression in trophoblastic cell lines. The 
increase in PIM1 and PIM3 in HTR8/SVneo cells upon LIF stimulation appeared to 
be consistent with the finding by another group (Aksoy et al. 2007) where PIM1 and 
PIM3 was unregulated by LIF via activation of the STAT3 pathway.  
PIM1 expression can be induced by several external stimuli in particularly by 
cytokines relevant in the immune system, which led to coining PIM1 kinase as a 
“booster” for the immune response (Bachmann und Moroy 2005). There are no 
comparisons so far related to PIM kinase functions between human trophoblast 
choriocarcinoma. Hence, in this study we have analyzed and compared the mRNA 
expression of PIM kinases in normal primary term trophoblast cells, the immortalized 
cell line HTR8/SVneo and the choriocarcinoma cell line JEG-3.   
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The results obtained from this study provide information about the expression of all 
three isoforms. PIM1 and PIM3 is evidently increased upon LIF stimulation in 
trophoblast cells, similar to the finding in inducing endothelial differentiation of cardiac 
stem cell via PIM1 up regulation (Iwakura et al. 2011). PIM3 was found to be highly 
enhanced in pre-malignant tissues in human hepatocellular carcinoma (Fujii et al. 
2005). 
PIM1 and PIM2 have been reported to be highly expressed in murine cells of 
hematopoietic origin and PIM kinases regulate the stability of SOCS-1 (Chen et al. 
2002). SOCS have been found to be regulated by cytokines in trophoblast cells 
(Fitzgerald et al. 2009). STAT3 mediates trophoblast invasion by LIF induction and 
are involved in the fine regulation of immunological and cellular responses (Fitzgerald 
et al. 2009) (Poehlmann et al. 2005b).  PIM1 kinase is expressed in human myeloid 
cells, which was induced by IL-3, G-CSF, GM-CSF and IL-6, which is supporting our 
study, results where LIF is a pleotropic function cytokine belonging to the IL-6 family 
(Lilly et al. 1992). This cytokine family is responsible for many biological responses 
that include immune response, inflammation, hematopoiesis and tumorigenesis by 
regulating the cell growth, survival and differentiation. All members use the common 
subunit receptor gp130 which activates the JAK/STAT pathway, where STAT3 plays 
a vital role in transmitting the signal from the cell membrane to the nucleus (Hirano et 
al. 2000). PIM1 kinase is associated esophageal squamous cell carcinoma. Its 
overexpression is related with poor prognosis  (Liu et al. 2010). PIM1 promotes 
tumorigenicity in human prostate cancer cell lines by c-MYC driven transcription 
activity (Kim et al. 2010). PIM1 protein expression is regulated by its 5'-untranslated 
region and Eukaryotic translation initiation factor 4E (elF-4E) (Hoover et al. 1997). 
PIM1 mRNA expression in prostate cancer serves as a diagnostic marker (He et al. 
2007). Due to high frequency of PIM1 expression in head and neck squamous cell 
cancer of different grades and stages in conjunction with its absence in non-
neoplastic head and neck squamous cell epithelium underlines the functional role of 
PIM1 in malign molecular processes (Beier et al. 2007). Frequent down-regulation of 
PIM1 mRNA expression in non-small cell lung cancer has been found in association 
with lymph node metastases (Warnecke-Eberz et al. 2008).  PIM1 is a direct 
transcriptional target of HOXA9 and a mediator of its anti-apoptotic and pro-
proliferative effects in early cells.  
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HOXA9 is frequently up-regulated in acute myeloid leukemia (Hu et al. 2007). It is 
also involved in endometrial receptivity which suggests a connection with PIM1 in 
early pregnancy (Xu et al. 2014a). PIM2 kinase plays a key role in ovarian cancer 
cells (Musiani et al. 2014). Survival under hypoxic conditions in cancer cells takes 
place as they remodel glucose metabolism to support tumor progression. HIF 
transcription factor is essential for cellular response to hypoxia. A regulatory 
feedback loop between HIF-1α and PIM2 in hepatocellular carcinoma (HepG2) cells 
was observed where PIM2 expression was induced upon hypoxia in a HIF-1α-
mediated manner. HIF-1α induced PIM2 expression, a regulatory mode which may 
be important for the adaptive responses and antagonizing hypoxia during tumor 
progression (Yu et al. 2014). Compared to benign, inflammatory and pre-malignant 
conditions, expression of PIM1 mRNA and protein increased significantly in 
pancreatic malignancies and the hypoxic cells displayed higher PIM1 mRNA and 
protein levels. So, the presence of PIM1 in tumor has a positive prognostic impact 
(Reiser-Erkan et al. 2008). PIM3 kinase is expressed in endothelial cells, promoting 
vascular tube formation (Zhang et al. 2009) (Yang et al. 2011). The work presented 
here demonstrates that all three isoforms of PIM kinases are constitutively expressed 
in trophoblast cells. Upon LIF stimulation the expression   increases in both cell lines 
which are chosen for this study.  PIM1 kinase bound to Hsp70 or Hsp90 remains 
active, emphasizing the importance of its overall cellular levels. PIM1 levels can be 
modulated in cells through degradation and stabilization. On protein level, the 
stability of PIM1 is regulated by Hsp90, Hsp70, and the ubiquitin-proteasome 
pathway (Shay et al. 2005). Upon LIF stimulation PIM1 expression in our trophoblast 
and choriocarcinoma cells was found to be localized in nuclei and cytoplasm as 
assessed by immunocytochemistry (ICC) and immunofluorescence (IF) staining. 
These observations coincide with findings of PIM1 expression in nuclei in normal 
gastric epithelial cells, but more pronounced in cytoplasm of human gastric tumors 
(Yan et al. 2012). PIM1 kinase expression in adipocytic neoplasms was localized to 
the cytoplasm (Nga et al. 2010) (Telerman et al. 1988). These findings are consistent 
with our current findings where immunostaining showed the expression of PIM1, 
PIM2 and PIM3 in both HTR8/SVneo and JEG-3 cell lines. PIM1 and PIM3 
expression was higher than PIM2 expression in HTR8/SVneo cells whereas in JEG-3 
cells, PIM2 and PIM3 were more expressed than PIM1.  
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Our investigation could demonstrate that PIM kinases play role in trophoblast cells 
during pregnancy. We have proven that LIF regulates this molecule which makes us 
to interpret, that LIF is the central mediator of both PIM induction and JAK/STAT 
pathway activation.  
In our study, the inhibition of PIM kinases resulted in induction of apoptosis and 
decrease in cell viability and cell proliferation. PIM kinase signaling is involved in 
many pathways, and thus the biological effects of its inhibitor SGI-1776 in trophoblast 
in comparison to choriocarcinoma cells might be multifaceted. SGI-1776 is a specific 
inhibitor for all three isoforms of PIM kinase activity. Significant transcription inhibition 
was observed in an acute myeloid leukemia (AML) cell line and in primary cells, 
which is similar to our findings that c-MYC driven transcription is disrupted by PIM 
kinase inhibition due to the decrease c-MYC (Ser62) phosphorylation (Fig 11.A) 
which is needed for c-MYC stability (Chen et al. 2011) (Kim et al. 2013). SGI-1776 
treatment in 4 Mantel cell lymphoma (MCL) cell lines resulted in apoptosis induction 
and Phosphorylation of transcription (c-MYC) (Yang et al. 2012). On cell viability nad 
proliferation extensive biochemical characterization of SGI-1776 confirmed its 
specificity for the three isoforms of the PIM family. Treatment of prostate cancer cells 
with SGI-1776 resulted in a dose-dependent reduction in phosphorylation of PIM 
kinase substrates that are involved in cell cycle progression and apoptosis. SGI-1776 
was able to reduce cell viability in a multidrug resistant prostate cancer cell line 
(Mumenthaler et al. 2009). Inhibition of PIM3 kinase causes growth inhibition of 
cancer cells by down regulating the expression of pSTAT3 (tyr705) (Chang et al. 
2010). Targeting PIM2 kinase by biochemical inhibitors impaired cell growth, 
decreased cisplatin-triggered BAD phosphorylation, and sensitized ovarian cancer 
cells to drug-induced apoptosis (Musiani et al. 2014). PIM2 kinase is an important 
target of treatment for tumor progression and bone loss in myeloma (Hiasa et al. 
2015). Chronic lymphocytic leukemia (CLL) cells when treated with SGI-1776 
resulted in a dose-dependent induction of apoptosis. Levels of the ant apoptotic 
protein BCL-XL were unchanged. However, levels of total c-MYC as well as 
phospho-c-MYC (Ser62), a PIM1 target, were decreased after SGI-1776 treatment 
(Chen et al. 2009b). 
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In murine hematopoietic cells PIM2 kinase phosphorylates BAD (ser112) and 
prevents BAD-induced cell death (Yan et al. 2003). PIM1 kinase promotes 
inactivation of the pro-apoptotic BAD protein by phosphorylating it at the ser112 
gatekeeper site (Aho et al. 2004). The c-myc gene is induced in response to the 
proliferative signals elicited by extracellular stimuli, including IL-6. The non-receptor 
tyrosine kinases c-src (Barone und Courtneidge 1995) and PIM1 induce BCL-2 
expression and inhibits c-MYC-induced apoptosis in a manner that is dependent on 
gp130-induced signals. PIM1 kinase acts as activator of the cell cycle pathway in 
neuronal death induced by DNA damage (Zhang et al. 2010).  
 
Further, stem cell-like features in three-dimensional (3D) in vitro cultures are used in 
cancer research as intermediate models between in vitro cell line cultures and in vivo 
tumor models. Spheroid (3D) cancer cell models have gained popularity in stem cell 
research. Spheroids and spheroid-like structures are characterized by their well-
rounded shape, the presence of cancer stem cells, and their capacity to be 
maintained as free-floating cultures. A multicellular tumor spheroid model was first 
described in the early 70s and obtained by culture of cancer cell lines under non-
adherent conditions (Weiswald et al. 2015). In addition, we describe here 
applications of spheroid cultures in trophoblast research to investigate the potential 
role of LIF which not only supports self-renewal of ESCs but also has a function in 
extra-embryonic development, where it promotes trophoblast proliferation, 
differentiation, and invasion (Poehlmann et al. 2005a) (Prakash et al. 2011) 
(Takahashi et al. 2003).  Upon LIF withdrawal, ESC differentiate but not to neural 
lineages (Ying et al. 2003). LIF supported the expansion of ESC but did not induce 
NANOG expression. LIF supports a totipotent state comparable to early embryonic 
cells that co-express embryonic and extra-embryonic determinants (Morgani et al. 
2013). There are reports suggesting suitable surface markers to characterize the 
stem cell-like features, which are CD44, CD34, CD24 and CD133. 
CD44, a hyaluronic acid receptor, is one of the most commonly studied surface 
markers, which is expressed by almost every tumor cell. CD24, a heat stable antigen, 
is another surface marker expressed in many tumor types (Jaggupilli und Elkord 
2012) (Ghosh et al. 2012). From the adenocarcinoma cell line generated spheroids 
express CD44 and CD133 as analyzed by flow cytometry (Liu et al. 2015). 
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In our study, we have characterized stem cell-like properties in HTR8/SVneo 
trophoblast cell models, by analyzing the surface molecules CD44, 34, 24 and 
CD133, and the transcription factors NANOG and CDX2.  STAT3 signaling regulates 
embryonic stem cell fate in a dose-dependent manner (Tai et al. 2014). CD44 and 
CD24 were used as CSC markers alone or in combination to identify cancer stem 
cells in tumors of the human female reproductive system (Lopez et al. 2013). 
Tumorigenic pancreatic cancer cells have been identified using the cell surface 
antigens CD44, CD24, and CD133 (Rasheed und Matsui 2012). Human primary 
colorectal cancer expresses specific phenotypic profiles, including CD133, CD24, 
and CD44 (Muraro et al. 2012) (Wang et al. 2012). Liver CSCs can be identified by 
several cell surface antigens, including CD133, CD90, CD44, Epithelial cell adhesion 
molecule (EpCAM) and CD133 (Liu et al. 2011) Breast cancer stem cells express the 
cell surface phenotype CD44+CD24-/low (Ginestier et al. 2007). High levels of CD44 
expression in breast cancer can be used as stem cell marker (Gong et al. 2015). In 
breast cancer stem cells, CD44 is involved in regulation of Notch 4 receptor signaling 
(Harrison et al. 2010). CD44 positive cells are characteristic markers for 
mesenchymal stem cells (NguyenThai et al. 2015). CD44 is expressed in 
hepatocellular carcinoma (Feng et al. 2014) and in lung cancer (Alamgeer et al. 
2013). A highly tumorigenic subpopulation of pancreatic cancer cells expresses the 
cell surface markers CD44, CD24, and epithelial-specific antigen (ESA) (Li et al. 
2007). Also head and neck squamous cell carcinomas express CD44 surface antigen 
(Sterz et al. 2010).  
Non-small cell lung cancer cells expressing CD44 have increased stem cell-like 
features (Leung et al. 2010). Therapeutic targeting of stem-like cancer cells via 
STAT3 modulation using a nanomedicine approach selectively reduces the CD44+ 
stem cell population in melanoma (Misra et al. 2015). CD34 is expressed in 
peripheral blood stem cells. It functions as adhesion molecule important for cell 
migration and regulation in hematopoiesis (Dercksen et al. 1995). Trans membrane 
CD34 glycoprotein is the most important marker for identification, isolation and 
enumeration of hematopoietic stem cells (HSCs) (Shafaghat et al. 2015).Hence the 
above mentioned studies,  supports our finding of  HTR8/SVneo cells expressing 
CD44,CD34 and CD24, which might be potential surface markers for characterizing 
stem cell-like features. 
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Transcription factors responsible for stem cells are many out of which we analysed 
the expression of NANOG and CDX2, these factors in human pluripotent stem cells 
is found to be highly expressed in colonies spontaneously differentiated in multiple 
lineages, including trophoblast cell lines. Cell lines exhibit totipotent potential and 
these properties may have implications for regulation of lineage decisions in the early 
embryo (Yang et al. 2015). NANOG stabilizes embryonic stem cells in culture by 
resisting or reversing alternative gene expression states (Chambers et al. 2007). 
Overexpression of NANOG reduces heterogeneity during embryonic stem cell 
maintenance. Interestingly, NANOG heterogeneity does not correlate with the 
heterogeneous expression of stage-specific embryonic antigen-1, suggesting that 
multiple but overlapping levels of heterogeneity may exist in embryonic stem cells 
(Singh et al. 2007). FACS analyses show that multipotent cytotrophoblast cells from 
human first trimester chorionic villi cells express markers typical for human stem cells 
such as SSEA4, OCT-4, ALP, and CD117. These are present within the 
cytotrophoblastic tissue of human fetal chorionic villus samples (CVSs) as also OCT-
4, NANOG, and SOX2 transcripts (Spitalieri et al. 2009). The differentiation of human 
embryonic stem cells down regulate the trophoblast lineage, the stemness markers 
POU5F1 (OCT4) and NANOG were markedly down-regulated, followed temporally 
by up-regulation of the CDX2, KRT7, HLA-G, ID2, CGA, and CGB trophoblast 
markers in presence of BMP4 (Marchand et al. 2011). Isolated and re-aggregated 
trophectoderm (TE) cells from full human blastocysts are able to develop into 
blastocysts with inner cell mass (ICM) cells expressing the pluripotency marker 
NANOG. In our hands, HTR8/SVneo cells expressed NANOG in monolayer culture 
and spheroids. Upon LIF stimulation, expression of NANOG at higher concentration 
(50 ng/ml) in spheroid culture was increased, whereas CDX2 expression was 
decreased at higher concentration, this might be due to the properties of LIF, as it is 
involved in feedback mechanism  
Moreover, the majority of the isolated TE cells which were repositioned in the center 
of the embryo do not sort back to their original position but integrate within the ICM 
and start to express NANOG (De Paepe et al. 2013). Human trophoblast stem cells 
express gene markers of both the trophectoderm and the inner cell mass. They 
exhibited genetic and biological characteristics similar to those of human embryonic 
stem cells, yet genetically distinct from placenta-derived mesenchymal stem cells. 
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Overexpression of transcription factor NANOG was possibly achieved through a 
retinoic acid (RA)-induced non-genomic c-Src/Stat3/Nanog signaling pathway 
mediated by the subcellular c-Src mRNA localization for the maintenance of 
pluripotency in trophoblast neural stem cells (tNSCs) in rats (Lee et al. 2012). 
Developmental expression of a number of genes was similar to that in murine 
embryos (OCT3B/4, CDX2, and NANOG). However, GATA6 is expressed throughout 
pre-implantation development in the human when cultured in Heparin-binding 
epidermal growth factor (HBEGF). LIF appears to facilitate human embryo 
expression of a number of genes. CDX2 expression is regulated by LIF, removal of 
LIF, stimulated CDX2 expression and induced formation of trophoblast stem cells 
(TSC) which then were able to differentiate into cells spongiotrophoblast and 
trophoblast giant cells (He et al. 2008). This result is consistent to our finding where 
CDX2 expression is decreased upon addition of LIF. When MBD3 knockdown cells 
were cultured in ES medium without LIF or in trophoblast stem (TS) cell medium, 
these cells differentiate into TE cells, which express CDX2 in mouse ES cells (Zhu et 
al. 2009) (Suwinska et al. 2010). Trophoblast stem cells under defined culture 
conditions express CDX2 in mice (Ohinata und Tsukiyama 2014). Cell growth was 
accelerated in an undifferentiated state sustained by LIF in ES cells (Iha et al. 2012). 
CD44 interaction activates stem cell marker NANOG, STAT3-mediated multi drug 
resistant gene (MDR1) gene expression in breast and ovarian tumor cells 
(Bourguignon et al. 2008). NANOG and STAT3 signaling promote microRNA-21 
expression and chemoresistance in hyaluronan/CD44-activated head and neck 
squamous cell carcinoma cells (Bourguignon et al. 2012). 
Our model showed an increase expression of NANOG and CDX2 in the spheroids 
with OSM treatment, whereas there was no change in surface markers CD44, CD34 
and CD24. OSM shares structure similarities and receptor with LIF (Rose und Bruce 
1991). It has been reported in one of the study that OSM and LIF reveal some similar 
biological functions in trophoblastic cells (Chaiwangyen et al. 2014).  Our studies 
exhibit that OSM and LIF (partially) induces the stem cell-like properties in 
trophoblast cell model HTR8/SVneo. To our knowledge, this is the first report that 
human OSM play a key role in maintaining stem cell-like properties.
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CHAPTER 6 CONCLUSION 
In conclusion, there have been studies done on investigating many molecules that 
are involved in several ways contributing its role in regulating to achieve a successful 
pregnancy. LIF being very important molecule during pregnancy was taken in the 
current study to elucidate the functions of PIM kinases in trophoblast. We 
characterized the expression of PIM kinases upon LIF stimulation and inhibiting their 
activities by using PIM-Kinase inhibitor IX, SGI-1776 (chemical inhibitor).  It was 
found that all the three PIM kinases (PIM1, PIM2 and PIM3) were expressed in both 
cell lines. The gene and protein expression level were shown to be increased upon 
LIF stimulation. Immunostianing data showed the localization and distribution of PIM 
kinases in both cells lines, respectively. The functional role of PIM kinase was 
elucidated in trophoblast cells where they play a vital role in cell survival and 
apoptosis. Further the trophoblast cell model has been characterized for stem cell 
like property by staining with surface antigen for studying the phenotype expression 
of the markers responsible for stem cell which are CD44, CD34, CD24 and CD133. 
The result demonstrated that cells were CD44+ve, CD34+ve, CD24+ and CD133-ve, 
proving the self-renewal property of HTR8/SVneo cell, and also expressed stem cell 
transcription factors NANOG, CDX2. These expressions were well studied as they 
were compared with monolayer culture 2D culture with 3D spheroid culture system, 
which provided the information regarding the cells ability to form spheroid that 
resembles stem cell-like features. Adding further, upon LIF stimulation, current study 
shows the decreased expression of surface markers, increased transcription factors 
at higher concentration, fulfilling another function of LIF to be having negative 
feedback loop mechanism. Hence these all above data provides a better 
understanding of the role of PIM kinases and stem cell-like features in trophoblast 
cells for successful pregnancy.   
 
Future Investigations  
To elucidate the PIM kinases expression in pregnancy pathology tissue samples and 
studies the functional analysis like migration, invasion in trophoblast cell models. 
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